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ABSTRACT
In the present study, voice onset time (VOT) measurements were compared
between a group of individuals with moderate Alzheimer’s disease (AD) and a group of
healthy age- and gender-matched peers. Participants read a list of
consonant-vowel-consonant (CVC) words, which included the six stop consonants.
Recordings were gathered and digitized. The VOT measurements were made from
oscillographic displays obtained from the Brown Laboratory Interactive Speech System
(BLISS) implemented on an IBM-compatible computer. VOT measures for the
participants’ six stop consonant productions were subjected to statistical analysis. The
results of the study indicated that differences in VOT values were not statistically
significant in the speakers with Alzheimer’s disease from the normal control speakers. 
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To those individuals living with Alzheimer’s disease.
vACKNOWLEDGMENTS
I would be remiss if I did not thank those special individuals who contributed to
my study. Foremost, I would like thank the twenty participants who unselfishly assisted
me in the data collection process. Your effort to aid a stranger without receiving
compensation is quite commendable. 
 Special gratitude goes to the individuals on my committee for their invaluable
knowledge and contributions. To Dr. Alejandro Brice, for his helpful suggestions and
whose knowledge of statistics proved immeasurable. To Dr. Janet Whiteside, for her
passion and useful input. You are truly a fantastic role model. To Dr. Ryalls, for his
patience and relentless support. You surpassed what was expected of an advisor; I am
delighted to call you a friend, Jack.
vi
TABLE OF CONTENTS
LIST OF FIGURES vii
LIST OF TABLES viii
CHAPTER ONE INTRODUCTION 1
Voice Onset Time Measurements 3
Voice Onset Time among Geriatric Speakers 4
Voice Onset Time among Aphasic Speakers 5
Speech Production of Individuals with Alzheimer’s Disease 7
Statement of the Problem 13
Purpose of the Study 13
Hypothesis 13
CHAPTER TWO  METHOD 15
Participants 15
Mini-Mental State Examination 16
Functional Linguistic Communication Inventory 17
Global Deterioration Scale 17
Consent 19
Instrumentation 20
Stimuli 20
Procedure 21
Acoustic Analyses 22
Voice Onset Time Measurements 22
Statistical Analysis of Data 25
Reliability 26
Expected Results 26
CHAPTER THREE RESULTS 27
Analysis of Data 32
Reliability 32
CHAPTER FOUR DISCUSSION 34
APPENDIX A CAREGIVER CONSENT FORM 43
APPENDIX B CONTROL CONSENT FORM 46
APPENDIX C INSTRUCTIONS TO SUBJECTS 48
APPENDIX D STIMULUS WORDS 50
APPENDIX E INDIVIDUAL DATA SHEETS 52
LIST OF REFERENCES 73
vii
LIST OF FIGURES
Figure 1: Positive Voice Onset Time (VOT) for a voiceless stop consonant (long lag). 23
Figure 2: Positive Voice Onset Time (VOT) for a voiced stop consonant (short lag). 24
Figure 3: Negative Voice Onset Time (VOT) for a prevoiced stop consonant. 24
viii
LIST OF TABLES
Table 1: Age of Participants (in years) 16
Table 2: CVC Stimuli Word List-Voiceless Consonants 21
Table 3: CVC Stimuli Word List-Voiced Consonants 21
Table 4: Average Word Duration and VOT Measurements of Voiceless Stops (in ms) 28
Table 5: Average Word Duration and VOT Measurements of Voiced Stops (in ms) 29
Table 6: Average VOT Measurements for AD and Control Participants (in ms) 30
Table 7: Average Word Duration Measurements for AD and Control Participants (in ms)
31
Table 8: Average VOT Measurements for Older Speakers (in ms) 38
Table 9: Participants Who Produced an Audible Swallow 40
Table 10: AD Participant #AM01 53
Table 11: AD Participant #AM02 54
Table 12: AD Participant #AM03 55
Table 13: AD Participant #AM04 56
Table 14: AD Participant #AM05 57
Table 15: AD Participant #AF01 58
Table 16: AD Participant #AF02 59
Table 17: AD Participant #AF03 60
Table 18: AD Participant #AF04 61
Table 19: AD Participant #AF05 62
Table 20: Control Participant #CM01 63
Table 21: Control Participant #CM02 64
Table 22: Control Participant #CM03 65
Table 23: Control Participant #CM04 66
Table 24: Control Participant #CM05 67
Table 25: Control Participant #CF01 68
Table 26: Control Participant #CF02 69
Table 27: Control Participant #CF03 70
Table 28: Control Participant #CF04 71
Table 29: Control Participant #CF05 72
ix
CHAPTER ONE
INTRODUCTION
Dementia causes a progressive decline in intellectual functioning, communicative
abilities, and personality traits (Payne, 1997). Alzheimer's disease is the most prevalent
form of dementia amongst older individuals, which is the result of structural and
biochemical changes in the brain (Johnson, 1997). According to Davis (2000),
“Alzheimer’s disease is one of several progressive and irreversible neuropathologies with
a gradual onset and relentless deterioration” (p. 27). It is characterized by short- and
long-term memory deficits, personality changes, and impaired abstract thinking and
judgment (Payne, 1997).
Currently, it is approximated that four million Americans carry the diagnosis of
Alzheimer’s disease, and the number is expected to rise to fourteen million by the year
2040. Given that Alzheimer’s disease primarily occurs in individuals older than 65-years
of age, the fastest growing population, its prevalence will vastly increase in the upcoming
decades. Individuals with Alzheimer’s disease live an average of ten-years following the
diagnosis and often require assistance; hence, Alzheimer’s disease is expensive. Health
planners have estimated the combined cost of caring for individuals with Alzheimer’s
disease to be 100 billion dollars per year, which is why the disease is being referred to as
xthe “disease of the 21st century” (Bayles, 2001). 
Early diagnosis offers the best opportunity to treat symptoms of the disease.
Presently, the only definite way to diagnose Alzheimer’s disease is to determine whether
neuritic plaques and neurofibrillary tangles exist in brain tissue. Neuritic plaques are
defined by Davis (1993, p. 142) as “granular deposits and remains of degenerated nerve
fibers.” Davis defines neurofibrillary tangles as “unusual triangular and looped fibers in
the cytoplasm or nerve cells.” To examine brain tissue, however, medical professionals
must wait until an autopsy can be performed. Consequently, only a diagnosis of
“possible” or “probable” Alzheimer’s disease can be made while the person is still alive.
Several clinical criteria may be employed to diagnose possible or probable Alzheimer’s
disease, including: (1) questions about the person's general health, current living
environment, previous medical problems, and the history of any difficulties the person
has carrying out daily activities, (2) tests of memory, attention, language, problem
solving, and counting, (e.g. Mini-Mental State Examination, Functional Linguistic
Communication Inventory, and Arizona Battery for Communication Disorders of
Dementia), (3) medical tests, such as tests of urine, blood, or spinal fluid, and (4) brain
scans (para. 20, "Alzheimer's Disease Education & Referral Center," n.d.).
The purpose of this study was to investigate whether there were subtle early signs
of Alzheimer’s disease in the speech signal, which were not apparent to the human ear. It
was believed that individuals with moderate Alzheimer’s disease might reveal a change in
voice onset time (VOT) production. The long-term goal of this study and additional
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studies to follow is to assist in the finding of a new and cost-effective way to detect
Alzheimer’s disease in its earliest stage. An explanation of VOT measurements follows.
Voice Onset Time Measurements
Previously conducted studies have established the use of voice-onset time (VOT)
in the production of normal and disordered speech, because it is a discrete temporal
measure. VOT can be defined as the distance between the release of an oral constriction
and the onset of glottal pulsing (Lisker and Abramson, 1964). Baken (1987) states, “many
facts point to VOT as a measure that is likely to be of use in describing or categorizing a
range of developmental, neuromotor, or linguistic disorders” (p. 375).
VOT directly relates to the linguistic difference between voiced and voiceless stop
consonants. The terms “voiced” or “voiceless” pertains to whether or not the vocal folds
are vibrating. Many words in the English language are differentiated only by the presence
or absence of voicing in the initial or final stop consonant. The production of a stop
consonant depends on a vowel, and given that all vowels are voiced, the vocal folds will
ultimately begin to vibrate. In voiced stop consonants, the voicing begins nearly
concurrently when the intra-oral air pressure is released. The voicing may even begin
before the release of the stop (i.e. pre-voicing). In voiceless stop consonants, however,
there is a delay in the onset of vocal fold vibration after the occlusion is released. This
delay in timing is referred to as VOT lag (Ryalls, 1996). A review of several studies
utilizing VOT in geriatric and aphasic populations follows.
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Voice Onset Time among Geriatric Speakers
The process of aging is becoming increasingly relevant, as the average age of the
world’s population increases; therefore, research into normal aging is speech production
is warranted. Ryalls, Simon, and Thomason (2002) conducted a study to broaden findings
for VOT productions in normally aging speakers. Normal older individuals participated in
the study that (1) had no known speech or language disorders, (2) were generally in good
health, and (3) were non-smokers. Twenty individuals participated, including ten males
with an average age of 57-years and ten females with an average age of 69-years. Stimuli
included eighteen consonant-vowel-consonant (CVC) real words used to elicit speech
productions, which included the six stop consonants (/p/, /t/, /k/, /b/, /d/, /g/), combined
with the three extreme vowels (/i/, /a/, /u/). Each participant produced each target word in
randomized order at least five times, while his or her speech productions were recorded.
The Brown Laboratory Interactive System (BLISS; Mertus, 1999) was used to perform
the acoustic measures of VOT and an analysis of variance (ANOVA) was performed on
the VOT measures for each speaker.
Results from this study revealed a strong, significant effect on age when compared
to a study based on the VOT production in younger speakers by Ryalls, Baldauff, and
Zipprer (1997). It was found that older speakers had larger negative values for voiced
stops (for instance, average VOT measures for /b/ in older speakers was –87 milliseconds,
as compared to –11 milliseconds in younger speakers). Furthermore, older speakers had
shorter VOT values for voiceless stops (for instance, average VOT measures for /p/ in
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older speakers was 59 milliseconds, as compared to 71 milliseconds in younger speakers).
Results of this study also revealed that younger female speakers had an overall syllable
duration average of 363 milliseconds, while older females had an overall total syllable
duration average of 494 milliseconds. Additionally, younger males had an overall syllable
duration average of 362 milliseconds, while older males had an overall total syllable
duration average of 439 milliseconds. These results demonstrate that older individuals
produce longer syllable durations.  It can be concluded from this study that the
relationship between VOT and speaking rates merit further investigation in the aging
process. For instance, additional studies investigating aging and speech production could
examine the VOT across monolingual and bilingual populations or include data gathered
in other geographic region of the United States. 
Voice Onset Time among Aphasic Speakers   
Blumstein, Cooper, Goodglass, Statlender, and Gottlieb (1980) examined the
speech production of speakers with aphasia by measuring VOT productions in order to
determine the extent to which speech errors are associated with phonetic as opposed to
phonemic disorders. Phonetic errors represent articulatory distortions of a specific
phonemic target and are typically produced by anterior non-fluent aphasics. Conversely,
phonemic errors involve the substitution of phonemes and are typically produced by
posterior fluent aphasics. Their study was based on the hypothesis that Broca’s aphasics
have specific phonetic deficits in motor speech planning. Thus, the selective predilection
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for phonetic errors serves as a means of distinguishing between alternative mechanisms
involved in speech deficits in aphasia. 
A total of eighteen participants were divided into five groups: five Wernicke’s
aphasics, four Broca’s aphasics, four conduction aphasics, one nonaphasiac dysarthric,
and four normal controls. The stimuli consisted of 30 monosyllabic real words, which
included an initial stop consonant (/p/, /t/, /k/, /b/, /d/, and /g/), followed by the vowel, /a/,
and by either one or two final consonants. Participants produced each target word a
minimum of eight times. Utterances were audio-recorded and were measured by
computer program. Phonemic transcriptions were made for those target words produced
in error. 
Broca’s aphasics’ productions of the target words exhibited abnormal overlapping
VOT distributions between voiced and voiceless English stop consonants. In contrast,
both the normal controls’ and Wernicke’s aphasics’ productions of the target words
exhibited two nonoverlapping distributions between the voiced and voiceless categories.
The results of this study revealed that all groups of aphasics demonstrated some deviation
in timing of articulation movements. As demonstrated by their percentage of phonetic and
phonemic errors, Broca’s aphasics showed a severe motor speech outputting disorder, as
measured by VOT. An average of 60% of their productions of the target words were
correct, 26 % included phonetic errors, and 14% included phonemic errors. Conduction
aphasics showed a moderate disorder. An average of 71% of their productions of the
target words were correct, 19 % included phonetic errors, and 10% included phonemic
errors. In contrast, Wernicke’s aphasics displayed minimal impairments. An average of
xv
92% of their productions of the target words were correct, 4% included phonetic errors,
and 4% included phonemic errors. Broca’s aphasics had statistically more phonetic errors
than the two other aphasic speaker groups. Thus, Blumstein et al. (1980) represents the
first acoustic data supporting the theory of a selective phonetic-level deficit in Broca’s
aphasia as measured by overlapping voiced and voiceless VOT productions. A review of
several studies including the speech production of individuals with Alzheimer’s disease
follows.
Speech Production of Individuals with Alzheimer’s Disease
 Cummings, Benson, Hill, and Read (1985) investigated the characteristics,
occurrence, and correlations of aphasic symptoms in dementia of the Alzheimer’s type.
The study was based on the theory that all Alzheimer’s disease patients demonstrate at
least some minimal degree of aphasic symptoms, such as anomia. Two groups of
participants were studied. The first group included 30 participants (seventeen males and
thirteen females) diagnosed with dementia of the Alzheimer’s type with a mean age of
71- years. To ensure the accuracy of dementia of the Alzheimer’s type diagnosis, the
participants were referred to the study following a screening interview, a neurological
examination, and a Mini-Mental State Examination (MMSE; Folstein, Folstein, &
McHugh, 1975) score of less than 24. The control group included 70 healthy participants
with a mean age of 42-years. Each control participant exhibited no evidence of dementia
or aphasia and scored higher than 24 on the MMSE.
xvi
 Participants were asked questions derived from the Boston Diagnostic Aphasia
Examination (Goodglass & Kaplan, 1972), theWestern Aphasia Battery (Kertesz, 1982),
a dysarthria scale, a category-naming test, and a reiterative speech disturbance scale.
Thirty-seven subscales measured (1) elements of auditory comprehension, (2) oral
reading, (3) spontaneous speech, (4) naming, (5) reading comprehension, (6) repetition,
(7) paraphasia, (8) writing, and (9) automatic speech. The participants were assigned a
scale value between zero (normal) and six (most abnormal).
The results demonstrated that control participants revealed no clinical evidence of
aphasia. In contrast, mean scores for dementia of the Alzheimer’s type participants
differed from zero on each subtest. “Language abnormalities were present in all dementia
of the Alzheimer’s type patients in the study, and the language alterations readily
distinguished the dementia of the Alzheimer’s type patients from control participants”
(pg. 396). Dementia of the Alzheimer’s type participants’ verbal output resembled
Wernicke’s aphasia in the later stages. In summary, Cummings, Benson, Hill, and Read
(1985) suggest that aphasia is a consistent symptom of dementia of the Alzheimer’s type.
Thus, of importance are the results from the study conducted by Blumstein, Cooper,
Goodglass, Statlender, and Gottlieb (1980), which revealed that all groups of aphasics
demonstrated some deviation in timing of articulatory movements, as measured by VOT. 
A longitudinal study by Romero and Kurz (1996) was conducted to measure the
rate and pattern of spontaneous speech decline in participants with Alzheimer’s disease
during a one-year follow-up. The study was based on the belief that the pattern of speech
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decline would have “prominent disturbances of communication and semantics, moderate
disturbances in automatic speech, but retained phonematic structures” (p. 35). Data and
results were recorded for 63 participants between the ages of 56- to 87-years, in which 30
participants had mild dementia severity and 33 participants had moderate dementia
severity, as measured by the Clinical Dementia Rating (Morris, 1993). Forty-six of the
participants were female, while seventeen participants were male. The stimuli consisted
of a rating scale section on the Aachener Aphasic Test (Huber, Poeck, Weniger, Willmes,
1983), a German language aphasia battery. The participants’ speech outputs were rated on
a scale ranging from zero (extremely disturbed) to five (undisturbed) in the following six
language areas: (1) communication, (2) articulation and prosody, (3) automatic speech,
(4) semantic structures, (5) phonematic structures, and (6) syntactic structures.
Romero and Kurz (1996) concluded “all six language scales showed that the
spontaneous speech of the patients was more impaired at the follow-up examination than
at baseline” (p. 37). In summary, the results demonstrated a general tendency for the
spontaneous speech of individuals with dementia to decrease upon a one-year follow-up
examination.
 Croot, Hodges, Xuereb, and Patterson (2000) investigated the theory that
articulatory and phonological impairments may occur in the early course of Alzheimer’s
disease. The purpose of their study was to augment the limited information concerning
the speech production of individuals with Alzheimer’s disease. The study involved ten
participants, including six participants with pathologically confirmed Alzheimer’s disease
via an autopsy and four participants with clinically diagnosed dementia of the
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Alzheimer’s type.  Four participants had progressive aphasia diagnosed as dementia of
the Alzheimer’s type from neuropsychological assessment, three participants had initial
amnestic syndrome with prominent phonological errors, one participant had mixed
progressive aphasia, one participant had nonfluent progressive aphasia, and one
participant had biparietal syndrome.
 Data on the participants’ speech production was collected from three speaking
frameworks including: 1) conversation, 2) single-word production in reading, naming,
and repetition tasks, and 3) speech series tasks, which included speaking and counting the
days of the week, the months of the year, and the alphabet. The three speech frameworks
were analyzed for the nature of errors and the overall severity of disturbance. Of
particular interest to these researchers were the types of speech production impairments
demonstrated in individuals diagnosed as dementia of the Alzheimer’s type by previous
studies including phonological paraphasias (e.g. /lat/ for /kat/), false-start
errors/hesitations, and reduced articulatory ease and fluency.
 The results from this study demonstrated that all participants produced
phonological paraphasias, false-start errors, and perseverations. Additionally, the
participants demonstrated hesitant and effortful speech often seen in nonfluent aphasias.
One aspect of speech production found to be impaired included access to phonological
forms from semantics, such that the participants were unable to correctly retrieve the full
phonological form, following an attempt to the retrieve the initial sound (hence, false start
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errors). Articulation was another aspect of the participants’ speech production found to be
impaired. Four out of the ten participants had a nonfluent speech disorder resembling
Broca’s aphasia. The data collected by these researchers suggests that the “integrity of
articulatory processing may on occasions be compromised in dementia of the Alzheimer’s
type. Thus, although rare as a symptom of Alzheimer’s disease, impaired
articulatory-motor aspects of speech production appear to be a feature of this disease in
some cases” (p. 301). Finally, when the focus is on less typical cases, it may be “revealed
that while phonological and articulatory abilities are not consistently disrupted in
Alzheimer’s disease, they are unmistakably impaired in some cases, even selectively, as a
presenting symptom” (p. 304).
Biassou, D’Esposito, Grossman, Hughes, Mickanin, Onishi, and Robinson (1995)
conducted a study to test the theory that Alzheimer’s disease patients would produce
more speech errors than healthy age-matched controls. The purpose of the study was to
quantify the frequency and nature of speech errors in patients with mild to moderate
Alzheimer’s disease. The study consisted of two groups of sixteen right-handed and
education-matched monolingual speakers of Standard American English. The first group
was diagnosed with mild to moderate Alzheimer’s disease according to the National
Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease
Related Disorders Association (NINCDS-ADRDA) and had a mean age of 69-years,
while the control group was neurologically intact and had a mean age of 70-years.
 The researchers assessed speech production by asking each participant to repeat
30 sentences, which were presented aurally and with natural prosodic contours. The
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sentences varied in length and syntactic structure: 36% were right-branching
constructions that contained terminal subordinate phrases, 27% were passive
constructions, 23% contained center-embedded subordinate phrases, 7% were
grammatically simple, and 7% contained pseudowords.
 Broad phonetic transcription of the participants’ recorded speech was made by a
“trained linguist” using the International Phonetic Alphabet (IPA). The recorded data was
analyzed for the sentences containing any phonological errors. Speech errors were
analyzed for whether they occurred in the initial, medial, or final position of a word, and
for whether the participants preserved the words’ syllabic structure. Furthermore, in order
to determine whether the phonemic errors were environmentally influenced, the authors
noted the frequency of phonemic substitutions, phonemic additions, metatheses, and
preservations. Random substitution errors and deletions were also tabulated.
 The results of this study suggested that sentences containing phonological errors
were significantly more frequent in individuals with Alzheimer’s disease than in the
control participants. The errors of participants with Alzheimer’s disease were
disproportionately in the word-initial position compared with the controls’ errors.
Additionally, Alzheimer’s disease participants were significantly more susceptible to
non-environmentally induced errors than the control group. Finally, the results indicated
that errors do occur in the speech production of individuals with Alzheimer’s disease.
Although the aforementioned studies demonstrated the presence of speech errors
in persons with Alzheimer’s disease, to our knowledge, no acoustic analyses of speech
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production in individuals with Alzheimer’s disease have been performed. The presence of
subtle acoustic differences, not apparent to the human ear, in the speech production of
individuals with Alzheimer’s disease may represent a new means of detecting the
presence of this disease. Therefore, it is proposed to conduct an acoustic investigation of
VOT in the speech production of individuals with Alzheimer’s disease, as outlined in the
next chapter.
Statement of the Problem
 Previously conducted studies have established the importance of the acoustic
characteristics of VOT in the production of speech (Baken, 1987). However, there has
been no research conducted, to this researcher’s knowledge, on the effects of Alzheimer’s
disease on VOT production measurements. The lack of acoustic data justifies a more
careful, in-depth view at the question of how Alzheimer’s disease may affect speech
production in subtle ways, such as VOT. 
Purpose of the Study
To investigate whether there were subtle early signs of Alzheimer’s disease in the
speech signal, which were not apparent to the human ear. It was believed that individuals
with moderate Alzheimer’s disease would reveal an overall shift toward smaller VOT
values (shorter positive VOT values for voiceless stops and longer negative VOT values
for voiced stops) based on the results of voice onset production measures in older
speakers (Ryalls, Simon, and Thomason, 2002).
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Hypothesis
It was hypothesized that there would be a progression in the changes of VOT
measures in individuals diagnosed with moderate Alzheimer’s disease aged 75- to
95-years to those healthy older individuals aged 75- to 95-years, following the analysis of
VOT production/measurements. VOT measurements were taken from the production of
18 CVC monosyllabic words containing the three-voiceless stop consonants of English,
(/p/, /t/, /k/), the three-voiced stop consonants of English, (/b/, /d/, /g/), and the peripheral
vowels, (/i/, /a/, /u/), and were measured by the Brown Laboratory Interactive Speech
System (BLISS) software package.
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CHAPTER TWO
METHOD
Participants
Two groups of participants, totaling ten individuals in each group, participated in
this study. Participants were recruited from an Alzheimer’s disease assisted living facility
and an elderly assisted living facility located in Central Florida. The first group of
participants consisted of ten individuals diagnosed with at least Stage 5 dementia,
according to the diagnostic criteria gathered from the stages for primary degenerative
dementia, per the Global Deterioration Scale (GDS; Reisberg, et al., 1982). The second
group of participants consisted of ten healthy age- and gender-matched individuals. Both
groups met the following criteria for participation: (1) between the ages of 75- and
95-years-old, (2) monolingual speaker of American English, (3) nonsmoking, (4)
produced an infrequent number of paraphasic errors, as judged by the researcher, in which
the participant produced less than five errors in a two-minute conversation, (5) able to
attend for an hour with minimal redirection, (6) have no respiratory difficulties, (7) have
no history of psychiatric or neurological disorder, other than Alzheimer’s disease, (8) not
taking antidepressant psychoactive medication, and (9) not demonstrate resistive
behaviors to the testing environment.
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The ages of the participants can be found in Table 1. The mean age of the
participants with Alzheimer’s disease was 86-years of age, with a standard deviation of
4.6-years. The youngest participant was 81-years of age and the oldest participant was
90-years of age. The mean age of the control participants was 85-years of age, with a
standard deviation of 5.1-years. The youngest participant was 77-years of age and the
oldest participant was 94-years of age. The participants were recruited throughout the
greater-Orlando area.
Table 1: Age of Participants (in years)
Participant Number 1 2 3 4 5 Average
AD Male 88 93 82 81 78 84
AD Female 83 87 85 88 90 87
Control Male 85 77 81 90 82 83
Control Female 86 94 87 80 82 86
Mini-Mental State Examination
TheMini-Mental State Examination (MMSE; Folstein, Folstein, & McHugh,
1975) is a concise, quantitative measure of cognitive status in adults. It can be used to
screen for cognitive impairment, approximate the severity of cognitive impairment at a
given point in time, track the course of cognitive changes in an individual over time, and
record an individual’s response to treatment. TheMMSE includes tasks to measure the
participant’s abilities in the following areas: 1) orientation, 2) registration, 3) attention
and calculation, 4) recall, 5) naming, 6) repetition, 7) three-stage command, 8) reading, 9)
writing, and 10) copying. Participants in the Alzheimer’s disease experimental group
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were limited to those who scored a 20 (out of 30) or below, while participants in the
control group were limited to those who scored a 25 or above.
Functional Linguistic Communication Inventory
To ensure Stage 5 dementia, the Functional Linguistic Communication Inventory
(FLCI; Bayles & Tomoeda, 1994) assessment battery was administered to participants
with Alzheimer’s disease. The FLCI is a standardized battery designed to quantify the
functional linguistic communication skills of moderately and severely demented
individuals. Acquiring knowledge about functional communication abilities is important
in order to obtain baseline information about the participants’ functional ability. The
FLCI is comprised of components used to evaluate the following ten functions: (1)
greeting and naming, (2) question and answering, (3) writing,  (4) sign comprehension
and object-to-picture matching, (5) word reading and comprehension, (6) ability to
reminisce, (7) following commands, (8) pantomime, (9) gesture, and (10) conversation.
An individual’s performance on the FLCI can be used to identify preserved functions and
predict functionally communication abilities at risk in the near future (Tomoeda, 2001).
The FLCI utilizes the diagnostic criteria gathered from the stages for primary
degenerative dementia, per the Global Deterioration Scale.
Global Deterioration Scale
The Global Deterioration Scale (GDS) was developed to provide caregivers with
an overview of the stages of cognitive function for individuals living with a primary
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degenerative dementia, such as Alzheimer's disease. It is divided into seven different
stages. Stages 1-3 are the pre-dementia stages, while Stages 4-7 are the dementia stages.
Beginning in Stage 5, an individual can no longer survive without assistance. Within the
GDS, each stage is numbered (1-7), given a short title, and followed by a brief listing of
clinical characteristics. By examining an individual's behavioral characteristics and
comparing them to the GDS, caregivers can obtain an approximation of where an
individual is situated in the disease process (Reisberg, et al., 1982).
Stage 1 is titled “No Cognitive Decline” and has the clinical characteristic of no
evident memory deficit. Stage 2 is titled “Very Mild Cognitive Decline” and has the
clinical characteristics of forgetting where one has placed familiar objects and forgetting
names of loved ones and friends. Stage 3 is titled “Mild Cognitive Decline” or “Mild
Cognitive Impairment” and has the following clinical characteristics: a) co-workers’
awareness of an individual’s poor performance; b) name and word finding deficits be;
c) loss of direction when traveling in unfamiliar location; and (d) misplacement of
valuable objects. Stage 4 is titled “Mild Cognitive Decline” or “Mild Dementia” and is
defined by the following clinical characteristics: (a) decreased knowledge of current and
recent events; (b) deficit in memory of one’s personal history; (c) flattened of affect and
withdrawal from challenging situations; and (d) decreased ability to travel, handle
finances, etc. Denial is a hallmark characteristic of Stage 4. Stage 5 is titled “Moderately
Severe Cognitive Decline” or “Moderate Dementia” and is defined by the following
clinical characteristics: (a) inability to recall a major relevant aspect in one’s current life,
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e.g., an address or telephone number of many years; (b) disorientation to time (date, day
of week, season, etc.) or to place; and (c) difficulty choosing the proper attire. Stage 6 is
titled “Severe Cognitive Decline” or “Moderately Severe Dementia” and is defined by the
following clinical characteristics: (a) intermittent forgetfulness of the name of the person
upon whom they are dependent for survival; (b) unawareness of all recent events and
experiences in their life; (c) retains vague knowledge of their past life; (d) unawareness of
their surroundings, the year, and the season; and (e) requires assistance with activities of
daily living. Personality and emotional changes occur in this stage including delusional
behavior, obsessive symptoms, anxiety symptoms, and loss of willpower. Stage 7 is titled
“Very Severe Cognitive Decline” or “Severe Dementia.” All verbal abilities are lost over
the course of this stage. Clinical characteristics include: (a) unintelligible utterances and
infrequent emergence of seemingly forgotten words and phrases; (b) requires assistance
during toileting and feeding; (c) loss of basic psychomotor skills; and (d) widespread
rigidity and developmental neurological reflexes are often present (Reisberg, et al., 1982).
Consent
All participants voluntarily signed an informed consent form in the presence of a
witness. Caregivers of those participants with Alzheimer’s disease also signed the consent
form. Consent forms had been approved by the University of Central Florida’s
Institutional Review Board (IRB). The IRB is a committee mandated by the National
Research Act, Public Law 93-348; to be established within each university or other
institution that performs research involving human participants. The purpose of the IRB
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is to determine whether a research plan involving human participants has adequately
included the ethical dimensions of the project by evaluating all proposals for human
research prior to the start of the research. All participants were assured of complete
confidentiality during his or her participation in the study.
Instrumentation
The participants’ speech was recorded in a quiet room on a Tascam DA-P1
portable Digital Audio Tape (DAT) recorder. An AKG Acoustics C420 headset with
miniature condenser microphone was used, which was positioned close to the corner of
the participants’ mouth. The participants’ recorded speech was digitized onto a hard drive
and measured acoustically using the Brown Laboratory Interactive Speech System
(BLISS) software package (Mertus, 1999).
Stimuli
 The speech stimuli included eighteen isolated monosyllabic
consonant-vowel-consonant (CVC) real words containing the three voiceless stop
consonants of American English, (/p/, /t/, /k/), or the three voiced stop consonants of
American English, (/b/, /d/, /g/), the peripheral vowels, (/i/, /a/, /u/), and ending in a
voiceless stop consonant. The vowels represent maximum differences in the relationship
of tongue placement in production (from /i/, the highest front vowel, to /u/, the highest
back vowel, and /a/, the lowest vowel). These three vowels are among the most common
vowels occurring in a variety of languages around the world (Kent, 1997). 
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The eighteen CVC monosyllabic real words were presented in random order and
printed in a large and easy-to-read font. To ensure good quality and reliability of each
participant’s speech production, all eighteen CVC syllables were recorded seven times.
Upon completion of the recording, the first three repetitions of each stimuli list were used
for acoustic analysis. Thus, four backup samples of each word were available for analysis
in the case of a phonemic substitution or acoustic interference.
Table 2: CVC Stimuli Word List-Voiceless Consonants
/p/  /t/  /k/
 /i/          peat         teak          keep
/a/                  pot           tot          cot
/u/          poop         toot          coup
Table 3: CVC Stimuli Word List-Voiced Consonants
/b/  /d/  /g/
 /i/          beat         deep          geek
/a/                  bop           dot          got
/u/          boot         dupe          goop
Procedure
xxx
The participants diagnosed with dementia were administered the FLCI and
MMSE, while control participants were only administered the MMSE. Each participant
was read the instructions and became familiarized with the procedure. The participants
were seated and fitted with a headset microphone. Each participant read a practice set to
ensure no phonemic substitutions occurred. The audio signal was monitored by
headphones to ensure that the instrumentation was working properly. The participants
then produced seven repetitions of the word list at a comfortable rate.  
Acoustic Analyses
 The recorded data of the participants’ production of the eighteen CVC syllables
were digitized onto a hard drive at the sampling rate of 20 kHz (set by BLISS), with a
12-bit quantization factor. Data were measured acoustically using the BLISS software
package that has been implemented on a Dell 486 (IBM-compatible) computer equipped
with a Zafiro digital sound card.
Voice Onset Time Measurements
 VOT measurements were performed using both auditory and visual cues obtained
from the oscillographic display of speech in BLISS. The parameters used to identify the
VOT interval were as follows: (1) placement of the first cursor was at the onset of the
burst (the point at which the stop consonant was released) and (2) placement of the
second cursor was at the highest point of the first cycle of the voiced portion of the
speech signal. Since there are typically many baseline crossings in the complex waveform
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of a vowel, the highest point of the first periodic cycle for the VOT measure was used, as
there is usually only a single and unique highest point in any particular cycle (Ryalls,
1996).  The time interval, measured in milliseconds, between the two cursors represented
the VOT interval for the stop consonant production.
 In addition to the visual measurement, the researcher listened to the marked
portion to ensure that the burst was properly isolated. Any prevoicing observed was
measured by placing the first cursor at the onset of periodic voicing and the second cursor
just before the burst. Figures 1, 2, and 3 are examples of how the first and second cursors
were placed depending on the type of VOT present. However, it should be noted that the
following figures do not represent the entire duration of a word, but rather the onset
portion of the production in order to demonstrate the VOT measure more clearly.
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Figure 1: Positive Voice Onset Time (VOT) for a voiceless stop consonant (long lag).
 Figure 1 is a depiction of the onset portion of a voiceless stop consonant, such as
/p/, /t/, or /k/ when viewed on an oscillographic display produced by BLISS. The left
cursor, represented by the first vertical line, was placed at the onset of the burst, while the
right cursor, represented by the second vertical line, was then placed at the highest point
of the first periodic cycle of the vowel portion of the speech signal. The time interval
between the two cursors was then displayed in milliseconds.
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Figure 2: Positive Voice Onset Time (VOT) for a voiced stop consonant (short lag).
 Figure 2 is a depiction of the onset portion of a voiced stop consonant, such as /b/,
/d/, or /g/ when viewed on an oscillographic display produced BLISS. The left cursor,
represented by the first vertical line, was placed at the onset of the burst, while the right
cursor, represented by the second vertical line, was then placed at the highest point of the
first periodic cycle of the vowel portion of the speech signal. The time interval between
the two cursors was then displayed in milliseconds.
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Figure 3: Negative Voice Onset Time (VOT) for a prevoiced stop consonant.
Figure 3 is a depiction of the onset portion of a prevoiced stop consonant, such as
/b/, /d/, or /g/ when viewed on an oscillographic display produced by BLISS. To complete
the measurements, the left cursor, represented by the first vertical line, was placed at the
onset of the prevoicing, while the right cursor, represented by the second vertical line,
was then placed at the burst. This is the only measurement that does not include the burst.
The time interval between the two cursors was then displayed in milliseconds. However,
unlike the voiceless and voiced measurements, which were measured in terms of positive
numbers, negative VOT would be represented by negative numbers. Prevoicing is
represented by negative numbers, because the vocal folds have begun to vibrate before
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the burst associated with the release.
Statistical Analysis of Data
Measures of central tendency (means and standard deviations) were calculated for
each individual participant for the VOT for each stop consonant in the VOT stimuli. VOT
averages were then calculated for each of the six stop consonants. A repeated measures
Multivariate Analysis of Variance (MANOVA) and a Two-way Analysis of Variance
(ANOVA) was used to compare the two groups of participants’ VOT measurements. The
between-group factor was individuals moderate Alzheimer’s disease versus healthy older
individuals. The within-group factors were voicing (voiced versus voiceless), place of
articulation (bilabial, alveolar, or velar), and gender.
Reliability
 To establish intrajudge reliability, the main investigator reanalyzed the data of one
randomly selected participant from each group (i.e. 10% of the population), and a Pearson
product-moment correlation was calculated between the two sets of VOT measures. 
To establish interjudge reliability, a second investigator measured the VOT data
of one different randomly selected participant from each group (i.e. 10% of the
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population), and a Pearson product-moment correlation was calculated between the two
sets of VOT measures. 
Expected Results
 It was expected that individuals with moderate Alzheimer’s disease would
demonstrate more signs of aging in VOT production than has been found in the group of
healthy older individuals. Specifically, it was anticipated that individuals with moderate
Alzheimer’s disease patients would produce shorter average VOT values for voiceless
stops and larger negative average values for voiced stops (Ryalls, Simon, and Thomason,
2003). It was hoped that the VOT measurements could then be used as an early
noninvasive behavioral indicator of those individuals most at risk for Alzheimer’s
disease.
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CHAPTER THREE
RESULTS
 Individual duration and VOT measures for each participant are listed in Appendix
F. There were a total of 108 measurements for each person, for a total of 2,160 individual
measures of word duration and VOT. The average word duration, VOT for place of
articulation (bilabial, alveolar, and velar), and overall average (X) of each voiceless stop
(/p/, /t/, and /k/) was calculated for each of the participants and are listed in Table 4. The
total word duration measurements and VOT values are in milliseconds.
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Table 4: Average Word Duration and VOT Measurements of Voiceless Stops (in ms)
AD
Males
/p/
Duration         VOT
/t/
Duration         VOT
/k/
Duration         VOT
1 429 56 433 80 431 91
2 597 79 806 79 752 92
3 780 115 817 113 761 97
4 639 61 507 57 557 84
5 600 71 656 71 586 80
X 609 76 644 80 617 89
AD
Females
/p/
Duration          VOT
/t/
Duration         VOT
/k/
Duration         VOT
1 683 101 660 136 693 156
2 562 52 611 51 540 60
3 790 67 1018 71 821 104
4 550 67 537 82 510 96
5 478 58 541 77 459 83
X 613 69 673 84 605 100
Control
Males
/p/
Duration         VOT
/t/
Duration         VOT
/k/
Duration         VOT
1 291 56 328 57 401 68
2 610 74 612 68 642 90
3 477 62 444 70 458 70
4 409 67 428 67 428 93
5 500 70 488 82 559 82
X 457 66 460 69 498 81
Control
Females
/p/
Duration         VOT
/t/
Duration          VOT
/k/
Duration        VOT
1 587 86 564 86 659 136
2 573 69 597 78 612 97
3 507 55 478 55 477 66
4 552 88 556 79 563 94
5 605 78 514 68 532 76
X 565 75 542 73 569 94
 According to Lisker and Abramson (1964), a voiceless stop would typically have
a long VOT, ranging from +60 to +100 milliseconds in American English. In the current
study, the range of VOT productions for voiceless stops ranged from was between +51 to
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+136 milliseconds. 
The average word duration, VOT for place of articulation (bilabial, alveolar, and
velar), and the overall average (X) of each voiced stop (/b/, /d/, and /g/) were calculated
for each of the participants and are listed in Table 6. As previously mentioned, the
duration measurements and VOT values are in milliseconds.
Table 5: Average Word Duration and VOT Measurements of Voiced Stops (in ms)
AD
Males
/b/
Duration          VOT
/d/
Duration         VOT
/g/
Duration         VOT
1 544 -133 480 -106 484 -61
2 617 -16 627 -71 752 5
3 948 -77 865 -17 669 -5
4 611 -38 386 -21 465 -20
5 655 17 594 23 744 18
X 675 -49 590 -38 623 -13
AD
Females
/b/
Duration          VOT
/d/
Duration         VOT
/g/
Duration         VOT
1 587 29 631 -20 755 35
2 707 -76 602 -25 817 -95
3 914 -6 710 -11 907 -6
4 623 -72 660 -70 630 -48
5 587 -51 767 -184 513 -24
X 684 -35 674 -62 724 -28
Control
Males
/b/
Duration          VOT
/d/
Duration         VOT
/g/
Duration         VOT
1 385 -97 398 -109 454 -82
2 729 -99 734 -101 719 -109
3 554 -42 459 19 418 9
4 452 -110 523 -141 494 -97
5 573 -86 582 -54 575 -35
X 539 -87 539 -77 532 -63
Control
Females
/b/
Duration          VOT
/d/
Duration         VOT
/g/
Duration         VOT
xl
1 623 -71 634 -106 699 -112
2 649 -126 655 -82 685 -94
3 499 -26 466 25 499 -9
4 583 17 616 -3 549 25
5 647 -68 649 -46 644 -60
X 600 -55 604 -42 615 -50
According to Lisker and Abramson (1964), a voiced stop would have a short
VOT, ranging from 0 to +25 milliseconds. In the current study, the range of VOT
productions for voiced stops was between +5 and +35 milliseconds. Table 5 also
demonstrates the third type of VOT that could occur, which is negative VOT or
prevoicing. The range of prevoicing that is demonstrated in Table 5 was between –3 and
–133 milliseconds. 
The averages of all VOT measures for place of articulation for participants with
Alzheimer’s disease (male and female) and control participants (male and female) were
calculated and can be found in Table 6. These averages indicate that the individuals with
Alzheimer’s disease produced longer VOTs for the voiceless stop consonants for each
place of articulation than the control participants. Additionally, these results reveal that
the individuals with Alzheimer’s disease produced smaller negative VOTs for the voiced
stop consonants for each place of articulation than the control participants.
Table 6: Average VOT Measurements for AD and Control Participants (in ms)
/p/ /t/ /k/ /b/ /d/ /g/
AD 73 82 95 -42 -50 -21
Control 71 71 88 -71 -60 -57
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Average VOT measurements for individuals with Alzheimer’s disease revealed
that the range of VOT productions for voiced stops ranged from +5 and +35 ms, while the
range of VOT productions for voiceless stops ranged from +51 to +136 ms. These results
indicate that individuals with Alzheimer’s disease exhibited two nonoverlapping
distributions between voiced and voiceless categories. Additionally, average VOT
measurements for the control speakers revealed that the range of VOT productions for
voiced stops ranged from +9 and +25 ms, while the range of VOT productions for
voiceless stops ranged from +55 to +136 ms. These results indicate that the control
speakers also exhibited two nonoverlapping distributions between voiced and voiceless
categories.
Average duration measurements can be found in Table 7. The average duration
measurements revealed that individuals with Alzheimer’s disease had an overall syllable
duration average of 627 ms for voiceless stops, while control individuals had an overall
total syllable duration average of 515 ms for voiceless stops. Additionally, individuals
with Alzheimer’s disease had an overall syllable duration average of 662 ms for voiced
stops, while control individuals had an overall total syllable duration average of 571 ms
for voiced stops. These results demonstrate that individuals with Alzheimer’s disease
produced longer syllable durations than healthy age-matched controls, indicating a
slightly slower speaking rate.
Table 7: Average Word Duration Measurements for AD and Control Participants (in ms)
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Voiceless Stops Voiced Stops
AD 627 662
Control 515 571
Analysis of Data
A repeated measures Multivariate Analysis of Variance (MANOVA) was
performed on the repeated trials of VOT data, using SPSS (2005). The F (2, 17) = .322
was not significant (p =.73). Subsequently, a two-way Analysis of Variance (ANOVA)
was performed on the averaged VOT data. As expected, there was a highly significant
effect of voicing [F (2, 17) = 220.36; p < .0001] indicating that both groups made a
significant distinction in VOT between voiceless and voiced stops. However, a two way
ANOVA for voiceless stops was not significant [F (1, 17) = .695; p = .42], nor was a two
way ANOVA for voiced stops significant [F (1, 17) 1.553; p =.23]; indicating that VOT
values were not statistically significantly different among the speakers with Alzheimer’s
disease from the normal control speakers. 
 A one-way ANOVA was performed for VOT comparing gender. The ANOVA for
voiceless stops did not show statically significant group effect for gender [F (1, 18) =
.199; p =.66], nor was there a gender group effect for voiced stops [F (1, 18) = .497;
p =.49]. A one-way ANOVA was also performed on average word durations. The results
were not statistically significant [F (1, 18) = 4.336; p >.05].
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Reliability
 To establish intrajudge reliability, the main investigator reanalyzed the data of one
randomly selected participant from each group (i.e. 10% of the population), and a Pearson
product-moment correlation was calculated between the two sets of VOT measures.
Intrajudge reliability was calculated at a correlation of r = 1.0 for both groups. 
To establish interjudge reliability, a second investigator measured the VOT data
of one different randomly selected participant from each group (i.e. 10% of the
population), and a Pearson product-moment correlation was calculated between the two
sets of VOT measures. Interjudge reliability was calculated at a correlation of r = .95 for
the control group and .94 for the group of individuals with Alzheimer’s disease.
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CHAPTER FOUR
DISCUSSION
The purpose of this study was to investigate whether there were subtle early signs
of Alzheimer’s disease in the acoustic signal of speech, which were not apparent to the
human ear. The present study compared VOT measurements between a group of
individuals with moderate Alzheimer’s disease and a group of healthy age- and
gender-matched peers. It was believed that individuals with moderate Alzheimer’s
disease might reveal an overall change in voice onset time (VOT) production. More
specifically, it was expected that individuals with moderate Alzheimer’s disease will
reveal an overall shift toward smaller VOT values (shorter positive VOT values for
voiceless stops and longer negative VOT values for voiced stops) based on the results of
voice onset production measures in older speakers (Ryalls, Simon, and Thomason, 2002).
The results of the study indicated that differences in VOT values were not
statistically significant in the speakers with Alzheimer’s disease from the normal control
speakers. Therefore, the hypothesis stating that there would be a progression in the
changes of VOT measures in individuals diagnosed with moderate Alzheimer’s disease
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aged 75- to 95-years to those healthy older individuals aged 75- to 95-years following the
analysis of VOT production/measurements was not supported by the data. An explanation
as to why a shift in VOT measurements were not produced by individuals with
Alzheimer’s disease is the fact that motor functioning, including speech, is relatively
spared throughout most of the disease course (Bayles, 2001).
While the results of the present study were not statistically significant, the large
amount of individual VOT measures collected, 1,080, supplements previous research
completed on VOT. In addition to the large amount of individual VOT measures, the
current study also augmented VOT research by providing VOT measurements of
individuals with an average age of 85-years.
Furthermore, to this investigator’s knowledge, there are no published studies
looking at VOT measurements of individuals with Alzheimer’s disease. Therefore, this
study is a novel application to the already popular use of VOT measurements when
comparing speech characteristics of two or more populations. For instance, studies of
VOT measurements have been used in studies comparing younger versus older speakers,
female versus male speakers (Ryalls, Simon, and Thomason, 2002), and Caucasian versus
African-American speakers (Ryalls, Zipprer, & Baldauff, 1997).
An interesting finding in the present study was the large percentage of prevoicing
that occurred during the production of voiced stop consonants. As previously mentioned,
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the range of prevoicing demonstrated in this study was between -3 and -133 ms.
Eighty-two percent (49/60) of the average VOT measurements of voiced stops for both
groups were prevoiced in this study. Reasons for the high percentage of prevoicing in this
study as compared to that of the popular VOT research completed by Lisker and
Abramson (1964), in which no prevoicing measurements were demonstrated in the results
include (1) the larger number of participants used in this study (twenty versus four) lead
to more variability in the speech signal among speakers, (2) the negative production
measurements (prevoicing) were included in the calculations of this study, while those
produced in the study by Lisker and Abramson were not, (3) better technology, including
computer-based measurements lead to more accurate calculations, and (4) a carrier phrase
was not used in the present study, which supports the thought that native American
English speakers may typically produce citation-form words with significant prevoicing.
 Comparisons between the VOT measurements of individuals with Alzheimer’s
disease in the current study to those of aphasic speakers from a study completed by
Blumstein, Cooper, Goodglass, Statlender, and Gottlieb (1980) were conducted.
Blumstein et al. revealed that all groups of aphasics demonstrated some deviation in
timing of articulatory movements, as measured by VOT. More specifically, Broca’s
aphasics’ productions of the target words exhibited abnormal overlapping VOT
distributions between voiced and voiceless English stop consonants. In contrast,
Wernicke’s aphasics’ productions of the target words exhibited two nonoverlapping
distributions between the voiced and voiceless categories. Thus, such a comparison of
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VOT measurements between individuals with Alzheimer’s disease and individuals with
aphasia is warranted, as previous studies have suggested that aphasia is a consistent
symptom of dementia of the Alzheimer’s type (Cummings, et al., 1985). 
The current study revealed that individuals with Alzheimer’s disease exhibited
two nonoverlapping distributions between voiced and voiceless categories, which were
also exhibited in the production of individuals with Wernicke’s aphasia. Furthermore,
Cummings et al. (1985) demonstrated that dementia of the Alzheimer’s type participants’
verbal output resembled Wernicke’s aphasia in the later stages. Therefore, further
research comparing the speech output between individuals with Alzheimer’s disease and
individuals with Wernicke’s aphasia may be warranted.
 Additional comparisons of VOT measurements were made between the healthy
control speakers used in the present study to those healthy older speakers used in the
study by Ryalls, Simon, and Thomason (2002). Ryalls et al. conducted a study to broaden
findings for VOT productions in normally aging speakers. The same speech stimuli were
used in both studies to elicit speech productions. A comparison between the speakers in
the two studies was completed to determine if the VOT measurements would vary
depending on the increasing age of the participants. The average age for the males in the
present study was 83-years, in comparison to 57-years in the study by Ryalls et al. The
difference in age between both groups of males was 26-years. The average age for the
females in the present study was 86-years, in comparison to 69-years in the study by
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Ryalls et al. The difference in age between both groups of females was 17-years. In total,
the average age for the older control speakers in the present study was 84.5-years
compared to the average age of 63-years from older speakers in the study by Ryalls et al.
The total average difference in age between both sets of groups was 21.5-years.
It was found that older speakers with an average age 84.5-years had smaller
negative values for voiced stops (for instance, average VOT measures for /b/ in older
speakers was –71 milliseconds, as compared to –87 milliseconds). Furthermore, older
speakers with an average age 84.5-years had longer VOT values for voiceless stops (for
instance, average VOT measures for /p/ in older speakers was 71 milliseconds, as
compared to 59 milliseconds). The results of the comparison does not support previous
research stating that older speakers would produce longer negative average VOT values
for voiced stops and shorter average VOT values for voiceless stops (Ryalls, Simon, and
Thomason, 2002). The averages of all VOT measures for place of articulation for
participants for the older control speakers (84.5-years) in the present study and the older
speakers (63-years) in the study by Ryalls et al. were calculated and can be found in Table
8. 
Table 8: Average VOT Measurements for Older Speakers (in ms)
Participant /p/ /t/ /k/ /b/ /d/ /g/
Older Speakers (84.5-years) 71 71 88 -71 -60 -57
Younger Speakers (63-years) 59 69 72 -87 -90 -76
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The average duration measurements revealed that the older individuals with an
average age 84.5-years of had an overall syllable duration average of 543 milliseconds,
while the older individuals with an average age 63-years of had an overall syllable
duration average of 467 milliseconds. These results demonstrate that older individuals
produce longer syllable durations than younger individuals. These results mirror those
found by Ryalls et al., in which the older speakers produced longer syllable durations than
younger speakers. However, the contrasting VOT measurement results between the two
studies merits further investigation in the VOT productions in normal aging speakers.
 An additional area warranting further research is the speech production of
individuals with Alzheimer’s disease. The majority of research completed on individuals
with Alzheimer’s disease has looked at their language abilities. Aside from the changes in
memory and personality, language disturbances represent a major characterizing factor in
Alzheimer’s disease, such as name and word finding deficits (Reisberg, et al., 1982). For
instance, in a study by Cummings, Benson, Hill, and Read (1985), it was found that
“Language abnormalities were present in all dementia of the Alzheimer’s type patients in
the study, and the language alterations readily distinguished the dementia of the
Alzheimer’s type patients from control participants” (p. 396). In the previously reviewed
literature, it was demonstrated that some individuals with Alzheimer’s disease
experienced speech disturbances following the acquisition of Alzheimer’s disease.
A longitudinal study by Romero and Kurz (1996) measured the rate and pattern of
lspontaneous speech decline in participants with Alzheimer’s disease during a one-year
follow-up. The results demonstrated a general tendency for the spontaneous speech of
individuals with dementia to decrease upon a one-year follow-up examination. Croot,
Hodges, Xuereb, and Patterson (2000) measured whether articulatory and phonological
impairments occurred in the early course of Alzheimer’s disease. The data suggested that
articulatory processing may occasionally be compromised in dementia of the Alzheimer’s
type, and may be a presenting symptom when the focus is on less typical cases. Biassou,
D’Esposito, Grossman, Hughes, Mickanin, Onishi, and Robinson (1995) measured the
amount of speech errors in Alzheimer’s disease patients. The results of this study
suggested that sentences containing phonological errors were significantly more frequent
in individuals with Alzheimer’s disease than in the control participants. In conclusion, the
results of these studies indicate that errors do occur in the speech production of
individuals with Alzheimer’s disease. Therefore, future studies on the speech production
of individuals with Alzheimer’s disease are warranted since the research in this area is
promising, yet sparse.
 An unexpected finding that occurred within the study was the discovery of an
“audible swallow” immediately preceding the speech production of a stop consonant in
some of the participants. This audible swallow was heard during five separate occasions
in the speech production of individuals with Alzheimer’s disease (occurring one time
each in three participants and twice in one participant). Additionally, the audible swallow
was heard during two separate occasions in the speech production of one control
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participant. Table 8 shows the participants who produced the audible swallow and on
which word the audible swallow was produced.
Table 9: Participants Who Produced an Audible Swallow
Participant Speech Stimuli Produced Following the Swallow
AM01 /dat/, /gat/
AF01 /dup/
AF04 /dat/
AF05 /dip/
CF02 /dup/, /dup/
MacNeilage & Davis (2005) theorized that speech evolved from the gestures
found in chewing and swallowing; perhaps the audible swallows heard in this study
reflect support for this theory. In aging and Alzheimer’s disease, we may see the
dissolution of speech gestures to earlier stages of their evolutionary development. It
appears to be a reflection of aging, in general, as it appeared in one control speaker. It
should be noted, however, that the control participant who produced the audible swallow
was the oldest participant in the study at 93-years of age. The detection of these audible
swallows merits further investigation, as it has never been previously observed in speech
production behaviors, to this researcher’s knowledge.
In summary, the present study has added to the ever-growing research currently
being completed on individuals with Alzheimer’s disease and supplemented the
groundwork for continuing research on the speech characteristics of individuals with
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Alzheimer’s disease. Results of this study demonstrated that VOT measurements could
not be used as an early investigative tool to detect Alzheimer’s disease in its earliest
stage. While the results of the present study were not statistically significant, it should not
diminish the effort of researchers to continue additional studies on the speech production
characteristics of individuals with Alzheimer’s disease, nor the search for earlier
indicators of Alzheimer’s disease. 
Future research may include an in-depth look into the amount and types of
paraphasic errors individuals with Alzheimer’s disease produce during structured,
imitative, and spontaneous speech. Additional research efforts may include comparing the
speech output between individuals with Alzheimer’s disease and individuals with
Wernicke’s aphasia due to the similarities within the groups’ VOT measurements. In
conclusion, further research on the speech characteristic of individuals with Alzheimer’s
disease is imperative to supplement our knowledge of the progressive and deteriorative
disease.
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APPENDIX A
CAREGIVER CONSENT FORM
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Dear Caregiver:
I am a graduate student in the Department of Communicative Disorders at the University
of Central Florida. I am investigating whether there are subtle early signs of Alzheimer’s
disease in the speech signal, which are not apparent to the human ear. Your family
member’s participation will increase the knowledge of the early signs of Alzheimer’s
disease and contribute to better understanding and care for persons with this debilitating
disease.
As part of the project, the Functional Linguistic Communication Inventory (FLCI) will be
administered to assess your family member’s functional communication abilities in order
to verify the level of severity. The FLCI takes approximately 15-25 minutes to administer.
Secondly, your family member will be administered the Mini-Mental State Examination
(MMSE) to measure his or her cognitive status. The MMSE takes approximately 5-10
minutes to administer. Next, your family member will be asked to read aloud a reading
passage and a list words into a microphone. His or speech will be recorded on an
audiotape, and then measured acoustically. This portion of testing is about 25-30 minutes
and can be done following the administration of the FLCI or during a separate session.
The entire project will take approximately 1 hour. It will take place over one to two
sessions. If you or your family member with Alzheimer’s disease does not wish to
participate in the tasks at any time, you can withdraw at any time. There are no risks
anticipated of any kind. You will not be compensated for your participation.
All activities will be completed at the Arden Courts. You and your family member’s
names will never be associated with the project. A number will code any information
obtained, and all tapes will be erased following the project’s completion.
If you have any questions regarding this project, please feel free to contact Julie Baker or
Dr. Jack Ryalls
Whom to contact about your rights in this study: UCFIRB Office, Office of Research,
University of Central Florida, Orlando Tech Center, 12443 Research Parkway, Suite 207,
Orlando, FL (407) 823-2901.
If you agree to participate in this project, please sign and return the attached consent form
to Julie Baker. Upon your request, a photocopy of this form will be given to you for your
records. By signing the consent form, you give us permission to report your family
member’s responses anonymously in the final manuscript of Julie Baker’s Master’s thesis
and to professional publications. I appreciate your time and cooperation.
Sincerely yours,
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Julie Baker, B.S., SLP     Jack Ryalls, Ph.D. 
Informed Consent
Please read this consent document carefully before you decide to participate in this study.
Project title: Speech Production Measures in Individuals with Alzheimer’s disease
Purpose of the study:
 The purpose of this research study is to examine the speech production of
individuals with Alzheimer’s disease. The hypothesis of this study is that those
individuals with Alzheimer’s disease will show greater indicators of aging in their speech
than their peers without Alzheimer’s disease.
What you will be asked to do in this study:
You will be asked to perform a session of two separate standardized memory tests
by answering questions and performing short memory tasks. You will be asked to read
aloud a list of short words and a short paragraph. Your voice will be recorded. You will
not be compensated for your participation.
Time required: approximately 50 to 60 minutes
Risks: There are no known risks to reading words and being tape-recorded.
Confidentiality:
 Your identity will be kept confidential. Your data will be assigned a confidential
code number and your name will not be used in any report of the data. Only Julie Baker
and Dr. Ryalls will have access to the tape recordings. The audiotapes will be erased
following the completion of the project.
Voluntary participation:
Your participation is voluntary. There is no penalty for not participating.
Right to withdraw from the study:
 You have the right to withdraw from the study at any time without consequence.
Whom to contact if you have questions about the study:
 Julie Baker, student in Communicative Disorders, University of Central Florida,
Orlando, FL.
Jack Ryalls, Ph.D. Department of Communicative Disorders, University of
Central Florida, Orlando, FL.
Whom to contact about your rights in the study:
UCFIRB Office, Office of Research, University of Central Florida, Orlando Tech
Center, 12443 Research Parkway, Suite 207, Orlando, FL (407) 823-2901
_______I have read the procedure described above.
_______I voluntarily agree to participate in this study, and if requested, I have received a
copy of this description.
_______________________________________________________/___ ___ ___
Caregiver /Guardian         Date
______________________________________________________/___ ___ ___
Student Investigator       Date
______________________________________________________/___ ___ ____
lvi
Supervisor/ Principal Investigator     Date
a: informed consent Alzheimer speech 2005.doc
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APPENDIX B
CONTROL CONSENT FORM
lviii
Informed Consent
Please read this consent document carefully before you decide to participate in this study.
Project title: Speech Production Measures in Individuals with Alzheimer’s disease
Purpose of the study:
 The purpose of this research study is to examine the speech production of
individuals with Alzheimer’s disease. The hypothesis of this study is that those
individuals with Alzheimer’s disease will show greater indicators of aging in their speech
than their peers without Alzheimer’s disease.
What you will be asked to do in this study:
You will be asked to perform a session standardized memory tests by answering
questions and performing short memory tasks. You will be asked to read aloud a list of
short words and a short paragraph. Your voice will be recorded. You will not be
compensated for your participation.
Time required: approximately 30 minutes
Risks: There are no known risks to reading words and being tape-recorded.
Confidentiality:
 Your identity will be kept confidential. Your data will be assigned a confidential
code number and your name will not be used in any report of the data. Only Julie Baker
and Dr. Ryalls will have access to the tape recordings. The audiotapes will be erased
following the completion of the project.
Voluntary participation:
Your participation is voluntary. There is no penalty for not participating.
Right to withdraw from the study:
 You have the right to withdraw from the study at any time without consequence.
Whom to contact if you have questions about the study:
 Julie Baker, student in Communicative Disorders, University of Central Florida,
Orlando, FL.
Jack Ryalls, Ph.D. Department of Communicative Disorders, University of
Central Florida, Orlando, FL.
Whom to contact about your rights in the study:
UCFIRB Office, Office of Research, University of Central Florida, Orlando Tech
Center, 12443 Research Parkway, Suite 207, Orlando, FL (407) 823-2901
_______I have read the procedure described above.
_______I voluntarily agree to participate in this study, and if requested, I have received a
copy of this description.
_______________________________________________________/___ ___ ___
Participant          Date
______________________________________________________/___ ___ ___
Student Investigator       Date
______________________________________________________/___ ___ ____
Supervisor/ Principal Investigator     Date
lix
a: informed consent Alzheimer speech 2005.doc
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APPENDIX C
INSTRUCTIONS TO SUBJECTS
lxi
Instructions
You are about to read some lists of words. First, you will be asked to read the
words aloud once to make sure you are reading them correctly. Next, you will read the
words aloud and be recorded. Please say your identification number clearly into the
microphone. Then, please read the words naturally into the microphone, as if you are
speaking with someone. Please read the repetition number at the top of every page and
then read all of the words listed on the page. This is not a race! Please do not go too fast,
but rather at a steady, natural pace. Thank you for your cooperation.
lxii
APPENDIX D
STIMULUS WORDS
lxiii
Word Lists
List 1 List 2 List 3 List 4 List 5 List 6 List 7
dot geek beat keep dot goop coop
keep teak bop tot cot peat pot
pot dot peat toot goop teak got
boot tot keep dupe deep geek peat
bop toot boot dot peat beat keep
toot deep tot poop teak tot teak
dupe coop dupe bop beat boot boot
peat boot dot goop geek got bop
tot goop poop teak keep keep goop
poop peat coop cot tot coop beat
deep cot geek deep dupe toot poop
got bop deep boot pot dot cot
coop pot teak peat toot bop deep
geek poop got beat got deep dot
beat beat goop geek coop poop dupe
cot got cot coop poop cot tot
teak keep toot got bop pot geek
goop dupe pot pot boot dupe toot
lxiv
APPENDIX E
INDIVIDUAL DATA SHEETS
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Table 10: AD Participant #AM01
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    444 1.     56 1.    388 1.     51 1.    402 1.     80
2.    438 2.     69 2.    533 2.     64 2.    417 2.     91
3.    417 3.     81 3.    438 3.     54 3.    452 3.     66
X    433 X     69 X    453 X     56 X    424 X     79
/a/ 1.    427 1.     63 1.    425 1.     89 1.    474 1.     96
2.    644 2.     54 2.    484 2.     96 2.    500 2.    113
3.    395 3.     56 3.    448 3.     96 3.    431 3.     99
X    489 X     58 X    452 X     94 X    468 X    103
/u/ 1.    352 1.     28 1.    350 1.     78 1.    387 1.     55
2.    359 2.     58 2.    438 2.    109 2.    430 2.    121
3.    382 3.     40 3.    394 3.     81 3.    388 3.     98
X    364 X     42 X    394 X     89 X    402 X     91
Total X    429 X     56 X    433 X     80 X    431 X     91
SD   15 SD   20 SD   21
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    418 1.   -67 1.    726 1.   -277 1.    421 1.     28
2.    679 2.  -277 2.    577 2.   -181 2.    441 2.     28
3.    740 3.  -177 3.    522 3.   -116 3.    339 3.     22
X    612 X  -174 X    608 X   -191 X    400 X     26
/a/ 1.    563 1.  -171 1.    337 1.    -70 1.    409 1.    -39
2.    398 2.   -86 2.    693 2.   -228 2.    603 2.   -122
3.    731 3.  -294 3.    269 3.     23 3.    699 3.   -181
X    564 X  -184 X    433 X    -93 X    570 X   -114
/u/ 1.    434 1.   -87 1.    336 1.     14 1.    412 1.      22
2.    460 2.    21 2.    373 2.     16 2.    509 2.   -128
3.    472 3.   -67 3.    486 3.  -133 3.    525 3.   -177
X    455 X   -44 X    398 X    -34 X    482 X    -94
Total X    544 X  -134 X    480 X   -106 X    484 X    -61
lxvi
SD  105 SD   111 SD   91
Table 11: AD Participant #AM02
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    617 1.    121 1.    987 1.     61 1.    519 1.    152
2.    679 2.     67 2.    599 2.     57 2.    688 2.    104
3.    691 3.     58 3.    895 3.     83 3.    773 3.     88
X    662 X     82 X    827 X     67 X    660 X    115
/a/ 1.    525 1.     72 1.    877 1.     87 1.    853 1.     93
2.    468 2.     83 2.    856 2.    108 2.    818 2.     80
3.    449 3.   137 3.    783 3.     75 3.    953 3.     90
X    481 X     97 X    839 X     90 X    875 X     88
/u/ 1.    460 1.     56 1.    957 1.     77 1.   1036 1.     81
2.    772 2.     67 2.    492 2.     81 2.    391 2.     58
3.    714 3.     51 3.    807 3.     85 3.    738 3.     81
X    649 X     58 X    752 X     81 X    722 X     73
Total X    597 X     79 X    806 X     79 X    752 X     92
SD   20 SD   15 SD   26
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    598 1.    -51 1.    651 1.   -101 1.    976 1.     21
2.    630 2.    -56 2.    512 2.     38 2.    957 2.     42
3.    607 3.     45 3.    601 3.     32 3.    790 3.    -54
X    612 X    -21 X    588 X    -10 X    908 X      3
/a/ 1.    720 1.    -50 1.    653 1.     24 1.    783 1.     39
2.    590 2.     14 2.    581 2.    -59 2.    437 2.    -39
3.    563 3.     11 3.    721 3.   -100 3.    818 3.     37
X    624 X     -8 X    652 X    -45 X    679 X     12
/u/ 1.    450 1.    -55 1.    593 1.   -121 1.    699 1.     12
2.    817 2.    -31 2.    728 2.   -296 2.    533 2.     38
3.    578 3.     27 3.    598 3.    -55 3.    777 3.    -54
lxvii
X    615 X    -20 X    640 X   -157 X    670 X     -1
Total X    617 X    -16 X    627 X    -71 X    752 X      5
SD   40 SD   104 SD   42
Table 12: AD Participant #AM03
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    946 1.    195 1.    621 1.     76 1.    555 1.    120
2.    721 2.    109 2.    814 2.    200 2.    849 2.    172
3.   1019 3.    181 3.    988 3.     77 3.    921 3.      95
X    895 X    162 X    808 X    118 X    775 X    129
/a/ 1.    684 1.    180 1.   1025 1.    157 1.    705 1.     66
2.    863 2.     77 2.    780 2.    160 2.    606 2.     86
3.    797 3.     71 3.    842 3.     93 3.    926 3.     82
X    781 X    109 X    882 X    137 X    746 X     78
/u/ 1.    428 1.     51 1.    794 1.     86 1.    842 1.     44
2.    743 2.    100 2.    776 2.     70 2.    707 2.    180
3.    821 3.     67 3.    716 3.     97 3.    736 3.     31
X    664 X     73 X    762 X     84 X    762 X     85
Total X    780 X    115 X    817 X    113 X    761 X     97
SD   56 SD   47 SD   52
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.   1261 1.  -165 1.   1032 1.    -50 1.    436 1.     18
2.    769 2.     29 2.    882 2.     20 2.    533 2.     18
3.    812 3.     29 3.    646 3.    -53 3.    726 3.  -123
X    947 X    -36 X    853 X    -28 X    565 X    -29
/a/ 1.    794 1.     19 1.    935 1.   -126 1.    640 1.     38
2.   1424 2.   -240 2.    752 2.    -54 2.    690 2.     30
3.   1157 3.   -231 3.    967 3.     33 3.    973 3.   -104
X   1125 X   -151 X    885 X    -49 X    768 X    -12
lxviii
/u/ 1.    802 1.  -234 1.    938 1.     20 1.    636 1.     26
2.    845 2.     73 2.    879 2.     27 2.    735 2.     35
3.    666 3.     24 3.    750 3.     32 3.    655 3.     13
X    771 X    -46 X    856 X     26 X    675 X     25
Total X    948 X    -78 X    865 X     -17 X    869 X     -5
SD   136 SD    56 SD   62
Table 13: AD Participant #AM04
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    1160 1.     66 1.    466 1.     74 1.    540 1.     70
2.     862 2.     49 2.    451 2.     40 2.    413 2.     96
3.     277 3.     70 3.    745 3.     35 3.    873 3.     73
X     766 X     62 X    554 X     50 X    609 X     80
/a/ 1.    322 1.     65 1.    445 1.     64 1.    337 1.     99
2.    749 2.     69 2.    282 2.     53 2.    304 2.     84
3.    345 3.     48 3.    315 3.     71 3.    323 3.     68
X    472 X     61 X    347 X     63 X    321 X     84
/u/ 1.   1064 1.     65 1.    845 1.     57 1.    901 1.     72
2.    564 2.     38 2.    735 2.     61 2.    625 2.     82
3.    413 3.     80 3.    278 3.     53 3.    695 3.    112
X    680 X     61 X    619 X     57 X    740 X     89
Total X    639 X     61 X    507 X     57 X    557 X     84
SD   13 SD   13 SD   15
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    497 1.     32 1.     442 1.     23 1.    445 1.    -41
2.    845 2.     25 2.    376 2.     22 2.    507 2.    -45
3.    605 3.    -97 3.    472 3.   -266 3.    348 3.     26
X    649 X    -13 X    430 X    -74 X    433 X    -20
/a/ 1.    824 1.      20 1.    363 1.    -64 1.    702 1.   -258
2.    332 2.   -109 2.    249 2.     24 2.    278 2.     22
lxix
3.    770 3.   -212 3.    286 3.     16 3.    323 3.     25
X    642 X   -100 X    299 X     -8 X    434 X     -70
/u/ 1.    790 1.      25 1.    536 1.     20 1.    375 1.     30
2.    411 2.    -51 2.    533 2.     13 2.    574 2.     35
3.    425 3.     25 3.    218 3.     21 3.    632 3.     28
X    542 X      0 X    429 X     18 X    527 X     31
Total X    611 X    -38 X    386 X   -21 X    465 X    -20
SD   86 SD   96 SD   95
Table 14: AD Participant #AM05
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    586 1.     73 1.    560 1.     81 1.    643 1.    121
2.    513 2.     39 2.    566 2.     72 2.    666 2.     93
3.    593 3.     90 3.    675 3.     66 3.    699 3.     87
X    564 X     67 X    600 X     73 X    669 X    100
/a/ 1.    743 1.     61 1.    835 1.     62 1.    436 1.     31
2.    717 2.     83 2.    548 2.     86 2.    466 2.     44
3.    456 3.     78 3.    603 3.     56 3.    460 3.     89
X    639 X     74 X    662 X     68 X    454 X     55
/u/ 1.    593 1.     91 1.    614 1.     72 1.    771 1.     79
2.    588 2.     61 2.    895 2.     86 2.    482 2.     90
3.    611 3.     61 3.    613 3.     56 3.    650 3.     86
X    597 X     71 X    707 X     71 X    634 X     85
Total X    600 X     71 X    656 X     71 X    586 X     80
SD   17 SD   12 SD   27
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    603 1.     20 1.    605 1.     23 1.    700 1.    -32
2.    488 2.      9 2.    507 2.     22 2.    656 2.    -36
3.    856 3.     15 3.    578 3.     14 3.    617 3.    -52
X    649 X     15 X    563 X     20 X    658 X    -40
lxx
/a/ 1.    763 1.     20 1.    435 1.     39 1.    704 1.     32
2.    491 2.     15 2.    726 2.     14 2.    774 2.     40
3.    673 3.      9 3.    509 3.     26 3.    661 3.     34
X    642 X     15 X    557 X     26 X    713 X     35
/u/ 1.    667 1.     20 1.    686 1.     20 1.    978 1.     66
2.    675 2.     17 2.    694 2.     23 2.    850 2.     60
3.    681 3.     28 3.    605 3.     25 3.    754 3.     53
X    674 X     22 X    662 X     23 X    861 X     60
Total X    655 X     17 X    594 X     23 X    744 X     18
SD    6 SD    7 SD   45
Table 15: AD Participant #AF01
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    641 1.    131 1.    578 1.    124 1.    731 1.    136
2.    571 2.     80 2.    649 2.    121 2.    722 2.    236
3.    658 3.    117 3.    668 3.    145 3.    752 3.    191
X    623 X    109 X    632 X    130 X    735 X    188
/a/ 1.    631 1.   103 1.    576 1.     92 1.    662 1.    156
2.    547 2.     74 2.    801 2.    221 2.    522 2.    111
3.  1135 3.     87 3.    793 3.    161 3.    721 3.    147
X    771 X     88 X    723 X    158 X    635 X    138
/u/ 1.    524 1.     86 1.    614 1.    106 1.    744 1.    128
2.    890 2.    143 2.    620 2.    120 2.    746 2.    176
3.    547 3.     84 3.    643 3.    132 3.    635 3.    125
X    654 X    104 X    626 X    119 X    708 X    143
Total X    683 X    100 X    660 X    136 X    693 X    156
SD    25 SD    38 SD    39
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    748 1.     29 1.    588 1.     21 1.    601 1.     51
lxxi
2.    522 2.     35 2.    617 2.     21 2.    740 2.     56
3.    570 3.     23 3.    569 3.     32 3.    619 3.     54
X    613 X     29 X    591 X     25 X    653 X     54
/a/ 1.    568 1.     38 1.    775 1.     14 1.    960 1.     38
2.    631 2.     28 2.    476 2.     13 2.    839 2.     21
3.    650 3.     32 3.    533 3.     16 3.    954 3.     23
X    616 X     33 X    595 X     14 X    918 X     27
/u/ 1.    532 1.     34 1.    714 1.   -153 1.    873 1.    14
2.    550 2.     20 2.    880 2.   -166 2.    607 2.    28
3.    516 3.     19 3.    523 3.     21 3.    604 3.    27
X    533 X     24 X    706 X    -99 X    695 X    23
Total X    587 X     29 X    631 X    -20 X    755 X    35
SD    7 SD    79 SD   16
Table 16: AD Participant #AF02
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    672 1.     42 1.    636 1.     55 1.    501 1.     66
2.    479 2.     44 2.    533 2.     84 2.    491 2.     63
3.    407 3.     31 3.    603 3.     44 3.    464 3.     52
X    519 X     39 X    591 X     61 X    485 X     60
/a/ 1.    479 1.     65 1.    650 1.     58 1.    529 1.     61
2.    726 2.     43 2.    554 2.     65 2.    517 2.     63
3.    564 3.    123 3.    670 3.     32 3.    461 3.     53
X    590 X     77 X    625 X     52 X    502 X     59
/u/ 1.    698 1.     33 1.    599 1.     66 1.    517 1.     62
2.    477 2.     52 2.    610 2.     35 2.    653 2.     63
3.    559 3.     34 3.    641 3.     22 3.    730 3.     57
X    578 X     40 X    617 X     41 X    633 X     61
Total X    562 X     52 X    611 X     51 X    540 X     60
SD   29 SD    20 SD    5
lxxii
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    755 1.   -281 1.    423 1.    -43 1.    548 1.    -91
2.    916 2.   -274 2.    638 2.     17 2.    890 2.    -97
3.    899 3.   -250 3.    582 3.    -84 3.    646 3.    -40
X    857 X   -268 X    548 X    -37 X    695 X    -76
/a/ 1.    674 1.     21 1.    595 1.     16 1.    775 1.     27
2.    656 2.     28 2.    542 2.    -33 2.   1100 2.   -317
3.    672 3.     29 3.    868 3.    -65 3.    928 3.   -228
X    667 X     26 X    666 X    -27 X    934 X   -173
/u/ 1.    440 1.     20 1.    472 1.     20 1.     655 1.     23
2.    717 2.     11 2.    633 2.    -73 2.   1040 2.     25
3.    634 3.     10 3.    674 3.     19 3.     767 3.   -160
X    597 X     14 X    593 X    -11 X     821 X    -37
Total X    707 X    -76 X    602 X    -25 X    817 X    -95
SD   144 SD    44 SD   121
Table 17: AD Participant #AF03
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.     769 1.      91 1.    1058 1.      24 1.     709 1.    114
2.     819 2.     101 2.    1354 2.     104 2.     770 2.    115
3.     724 3.      77 3.    1202 3.     103 3.     909 3.    144
X     771 X      90 X    1205 X      77 X     796 X    124
/a/ 1.     787 1.      85 1.     771 1.      99 1.    1031 1.    147
2.     980 2.      34 2.     933 2.      85 2.     726 2.      97
3.     929 3.      86 3.     794 3.      70 3.     728 3.      91
X     899 X      68 X     833 X      85 X     828 X     112
/u/ 1.     744 1.      71 1.     807 1.      48 1.   1440 1.      73
2.     587 2.      36 2.     888 2.      38 2.     475 2.    109
3.     772 3.      23 3.    1351 3.      72 3.     605 3.      43
X     701 X      43 X    1015 X      53 X     840 X       75
Total X     790 X      67 X    1018 X      72 X     821 X      104
SD    29 SD    29 SD      33
lxxiii
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    1088 1.     42 1.    852 1.   -100 1.    936 1.     17
2.    1114 2.   -134 2.   1012 2.   -177 2.   1139 2.   -134
3.     819 3.     18 3.    506 3.      23 3.    828 3.      33
X    1007 X    -25 X    790 X     -85 X    968 X     -28
/a/ 1.    729 1.     47 1.    568 1.      21 1.    966 1.     24
2.    825 2.    -23 2.    922 2.      32 2.    791 2.     14
3.   1024 3.     42 3.    763 3.      31 3.    873 3.     21
X    859 X     22 X    751 X      28 X    877 X     20
/u/ 1.    602 1.     52 1.    526 1.      11 1.    950 1.     20
2.   1063 2.  -127 2.    576 2.      24 2.    460 2.     20
3.    961 3.     25 3.    668 3.      39 3.   1220 3.    -73
X    875 X    -17 X    590 X      25 X     877 X    -11
Total X    914 X      -7 X    710 X     -11 X     907 X     -6
SD    74 SD     75 SD    57
Table 18: AD Participant #AF04
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    646 1.     52 1.    570 1.     36 1.    577 1.    107
2.    522 2.     67 2.    547 2.     86 2.    348 2.     79
3.    521 3.     73 3.    500 3.     84 3.    426 3.     88
X    563 X     64 X    539 X     69 X    450 X     91
/a/ 1.    342 1.     62 1.    678 1.     91 1.    663 1.     82
2.    541 2.     67 2.    307 2.     58 2.    469 2.    100
3.    641 3.     86 3.    581 3.     99 3.    557 3.     83
X    508 X     72 X    522 X     83 X    563 X     88
/u/ 1.    481 1.     72 1.    504 1.     97 1.    624 1.    130
2.    725 2.     79 2.    575 2.   106 2.    429 2.     86
3.    529 3.     49 3.    572 3.     80 3.    493 3.    107
X    578 X     67 X    550 X     94 X    516 X    108
lxxiv
Total X    550 X     68 X    537 X     82 X    510 X     96
SD   12 SD   22 SD   17
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    623 1.   -128 1.    773 1.   -115 1.    633 1.    -74
2.    804 2.   -285 2.    546 2.   -105 2.    720 2.     23
3.   1069 3.    -76 3.    657 3.    -84 3.    800 3.   -207
X    832 X   -163 X    659 X   -101 X    718 X    -86
/a/ 1.    366 1.     11 1.    715 1.     38 1.    628 1.     44
2.    483 2.     17 2.    386 2.    -94 2.    624 2.    -28
3.    385 3.     22 3.    965 3.     17 3.    515 3.    -48
X    411 X     17 X    689 X    -13 X    589 X    -11
/u/ 1.    587 1.    -98 1.    655 1.     15 1.    627 1.   -130
2.    802 2.   -154 2.    491 2.  -112 2.    566 2.     25
3.    492 3.     40 3.    753 3  .-186 3.    558 3.    -38
X    627 X    -71 X    633 X    -94 X    584 X    -48
Total X    623 X    -72 X    660 X    -69 X    630 X    -48
SD  107 SD    76 SD    81
Table 19: AD Participant #AF05
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    565 1.     64 1.    603 1.     85 1.    517 1.      89
2.    461 2.     45 2.    510 2.     75 2.    472 2.    103
3.    468 3.     50 3.    666 3.     76 3.    491 3.    103
X    461 X     53 X    593 X     79 X    493 X     98
/a/ 1.    296 1.     77 1.    276 1.     88 1.    284 1.     77
2.    707 2.     37 2.    467 2.     64 2.    559 2.     32
3.    435 3.     63 3.    567 3.     50 3.    318 3.     58
X    479 X     59 X    437 X     67 X    387 X     56
/u/ 1.    471 1.     43 1.    521 1.     82 1.    592 1.    114
lxxv
2.    404 2.     74 2.    692 2.     80 2.    458 2.     75
3.    603 3.     66 3.    562 3.     89 3.    445 3.     93
X    493 X     61 X    592 X     84 X    498 X     94
Total X    478 X     58 X    541 X     77 X    459 X     83
SD   14 SD   13 SD   26
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    444 1.     20 1.    716 1.   -242 1.    570 1.    -32
2     462 2.     29 2.    546 2.    -80 2.    823 2.    -63
3.    833 3.   -180 3.    826 3.   -293 3.    547 3.    -60
X    580 X    -44 X   696 X   -205 X    647 X   -52
/a/ 1.    631 1.    -54 1.  1371 1.   -688 1.    272 1.     32
2.    495 2.     27 2.    939 2.   -226 2.    507 2.    -28
3.    721 3.     28 3.    629 3.     44 3.    494 3.    -25
X    616 X      0 X    980 X   -290 X    424 X     -7
/u/ 1.    618 1.    -304 1.    627 1.   -160 1.    437 1.     15
2.    499 2.     30 2.    564 2.     22 2.    440 2.     13
3.    576 3.     -62 3.    685 3.    -36 3.    527 3.    -71
X    564 X  -111 X    625 X    -58 X    468 X    -14
Total X    587 X    -52 X    767 X   -184 X    513 X    -24
SD   117 SD   223 SD   37
Table 20: Control Participant #CM01
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.     519 1.    66 1.     500 1.    66 1.    471 1.   56
2.     463 2.    51 2.     534 2.    70 2.    242 2.   67
3.     268 3.    46 3.     398 3.    40 3.    464 3.   92
X     417 X    54 X     477 X    59 X    392 X   72
/a/ 1.     279 1.    91 1.     279 1.    79 1.    505 1.   63
2.     247 2.    39 2.     340 2.    58 2.    271 2.   58
lxxvi
3.     235 3.    43 3.     258 3.    56 3.    247 3.   49
X     254 X    58 X     292 X    64 X    341 X   57
/u/ 1.     212 1.    62 1.     237 1.    45 1.    520 1.   99
2.     202 2.    48 2.     241 2.    68 2.    437 2.   75
3.     194 3.    56 3.     166 3.    30 3.    451 3.   55
X     203 X    55 X     215 X    48 X    469 X   76
Total X     291 X    56 X    328 X    57 X    401 X   68
SD  16 SD  16 SD 17
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.     489 1.    -81 1.     568 1.  -180 1.    690 1.   -94
2.     355 2.   -126 2.     315 2.  -112 2.    683 2.  -119
3.     447 3.    -70 3.     217 3.   -42 3.    585 3.   -90
X     430 X    -92 X     367 X  -111 X    653 X   -70
/a/ 1.     337 1.    -60 1.     379 1.  -120 1.    306 1.   -32
2.     360 2.  -128 2.     354 2.   -78 2.    319 2.   -60
3.     305 3.   -92 3.     378 3.  -122 3.    301 3.   -97
X     334 X   -93 X     370 X  -107 X    309 X   -63
/u/ 1.     536 1.  -127 1.     532 1.  -100 1.    621 1.   -79
2.     331 2.  -104 2.     519 2.   -98 2.    304 2.   -74
3.     304 3.   -89 3.     323 3.  -131 3.    279 3.   -89
X     390 X  -107 X     458 X  -110 X    401 X   -81
Total X     385 X    -97 X     398 X  -109 X    454 X   -71
SD   25 SD  38 SD  25
Table 21: Control Participant #CM02
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    452 1.   77 1.    524 1.   59 1.    594 1.  101
2.    619 2.   89 2.    675 2.   75 2.    667 2.   92
3.    642 3.   71 3.    583 3.   70 3.    643 3.  103
X    571 X   79 X    594 X   68 X    635 X   99
lxxvii
/a/ 1.    626 1.   81 1.    634 1.   63 1.    757 1.   65
2.    577 2.   83 2.    693 2.   61 2.    726 2.   80
3.    626 3.   63 3.    604 3.   70 3.    625 3.   83
X    610 X   76 X    644 X   65 X    703 X   76
/u/ 1.    761 1.   52 1.    635 1.   73 1.    601 1.   80
2.    679 2.   79 2.    578 2.   67 2.    610 2.  112
3.    503 3.   66 3.    582 3.   72 3.    549 3.   91
X    648 X   66 X    598 X   71 X    587 X   94
Total X    610 X   74 X    612 X   68 X    642 X   90
SD 12 SD  6 SD 14
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    656 1.   17 1.    671 1.  -80 1.    811 1.  -98
2.    726 2. -125 2.    777 2. -142 2.    651 2.  -97
3.    886 3. -211 3.    865 3. -118 3.    725 3. -147
X    756 X -106 X    771 X -113 X    729 X -114
/a/ 1.    583 1.   18 1.    903 1. -169 1.    877 1.  -96
2.    758 2. -156 2.    874 2. -131 2.    819 2. -119
3.    674 3.  -44 3.    629 3.   23 3.    691 3. -111
X    672 X  -61 X    802 X  -92 X    796 X -109
/u/ 1.    775 1.  -96 1.    681 1. -122 1.    587 1.  -84
2.    710 2. -130 2.    612 2.  -86 2.    672 2. -126
3.    791 3. -166 3.    593 3.  -90 3.    637 3. -102
X    759 X -131 X    629 X  -99 X    632 X -104
Total X    729 X  -99 X    734 X -101 X    719 X -109
SD  81 SD  55 SD  19
Table 22: Control Participant #CM03
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    458 1.   75 1.    456 1.   81 1.    489 1.   83
lxxviii
2.    500 2.   64 2.    478 2.   66 2.    461 2.   81
3.    527 3.   54 3.    451 3.   52 3.    405 3.   69
X    495 X   64 X    462 X   66 X    452 X   78
/a/ 1.    451 1.   61 1.    438 1.   86 1.    469 1.   87
2.    517 2.   67 2.    390 2.   86 2.    485 2.   83
3.    473 3.   48 3.    497 3.   73 3.    524 3.   81
X    480 X   59 X    442 X   82 X    493 X   84
/u/ 1.    525 1.   64 1.    478 1.   61 1.    441 1.   59
2.    398 2.   54 2.    402 2.   52 2.    423 2.   30
3.    441 3.   70 3.    400 3.   75 3.    425 3.   60
X    455 X   63 X    427 X   63 X    430 X   50
Total X    477 X   62 X    444 X   70 X    458 X   71
SD  9 SD 13 SD 18
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    576 1.   -90 1.    484 1.  -46 1.    425 1.   28
2.    596 2. -141 2.    486 2.   39 2.    482 2.  -62
3.    605 3.  -92 3.    500 3.   29 3.    448 3.   37
X    592 X -108 X    490 X    7 X    452 X    1
/a/ 1.    485 1.  -96 1.    415 1.   21 1.    426 1.  -21
2.    719 2.   34 2.    396 2.   22 2.    418 2.   37
3.    439 3.   28 3.    391 3.   14 3.    434 3.   19
X    548 X  -11 X    401 X   19 X    426 X   12
/u/ 1.    536 1.   35 1.    365 1.   17 1.    391 1.   46
2.    404 2.   33 2.    623 2.   41 2.    357 2.  -26
3.    629 3. -93 3.    474 3.   34 3.    383 3.   23
X    523 X   -8 X    487 X   31 X    377 X   14
Total X    554 X  -42 X    459 X   19 X    418 X    9
SD 73 SD 26 SD 37
Table 23: Control Participant #CM04
lxxix
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    362 1.   66 1.    405 1.   23 1.    448 1.   92
2.    419 2.   80 2.    525 2.   88 2.    463 2.   91
3.    401 3.   85 3.    437 3.   40 3.    438 3.   94
X    394 X   77 X    456 X   50 X    450 X   92
/a/ 1.    431 1.   79 1.    395 1.   73 1.    415 1.   92
2.    422 2.   65 2.    407 2.   79 2.    369 2.   72
3.    445 3.   31 3.    444 3.   87 3.    399 3.   80
X    433 X   58 X    415 X   80 X    394 X   81
/u/ 1.    419 1.   70 1.    443 1.   76 1.    482 1.  105
2.    376 2.   57 2.    415 2.   66 2.    401 2.  101
3.    404 3.   71 3.    379 3.   69 3.    439 3.  109
X    400 X   66 X    412 X   70 X    441 X  105
Total X    409 X   67 X    428 X   67 X    428 X   93
SD 16 SD 22 SD 12
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    483 1. -117 1.    513 1. -145 1.    565 1. -172
2.    486 2.  -61 2.    531 2. -123 2.    562 2.  -88
3.    496 3. -159 3.    504 3. -112 3.    567 3. -187
X    488 X -112 X    516 X -127 X    565 X -149
/a/ 1.    541 1. -187 1.    600 1. -218 1.    348 1.  -94
2.    521 2. -118 2.    496 2.  -95 2.    471 2. -114
3.    514 3. -102 3.    452 3. -100 3.    460 3. -111
X    525 X -135 X    516 X -138 X    426 X -106
/u/ 1.    486 1.   23 1.    548 1. -168 1.    498 1.   22
2.    533 2. -154 2.    521 2. -115 2.    504 2.   15
3.    497 3. -116 3.    539 3. -195 3.    469 3. -147
X    343 X  -82 X    536 X -159 X    490 X  -37
Total X    452 X -110 X    523 X -141 X    494 X  -97
SD  61 SD  44 SD  74
lxxx
Table 24: Control Participant #CM05
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    420 1.   44 1.    472 1.   95 1.    578 1.  102
2.    565 2.   46 2.    487 2.   90 2.    488 2.   67
3.    458 3.   60 3.    634 3.   73 3.    607 3.   72
X    481 X   50 X    531 X   86 X    538 X   80
/a/ 1.    484 1.   98 1.    483 1.   98 1.    731 1.   86
2.    643 2. 108 2.    486 2.  101 2.    455 2.   78
3.    547 3.   91 3.    487 3.   79 3.    618 3.   75
X    558 X   99 X    485 X   93 X    538 X   80
/u/ 1.    433 1.   72 1.    379 1.   65 1.    518 1.   77
2.    551 2.   57 2.    423 2.   58 2.    540 2.   95
3.    397 3.   50 3.    539 3.   75 3.    558 3.   85
X    460 X   60 X    447 X   66 X    539 X   86
Total X    500 X   70 X    488 X   82 X    559 X   82
SD 24 SD 15 SD 11
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    623 1.  -78 1.    472 1. -111 1.   686 1. -131
2.    618 2.  -98 2.    494 2.  -90 2.   713 2. -117
3.    497 3.  -52 3.    634 3.   24 3.   443 3.  -50
X    579 X  -76 X    533 X  -59 X   614 X  -99
/a/ 1.    598 1. -129 1.    625 1.  -47 1.   486 1.   18
2.    820 2. -103 2.    678 2.  -43 2.   620 2.   21
3.    596 3.  -54 3.    708 3.  -78 3.   594 3.   19
X    671 X  -95 X    670 X  -56 X   567 X   19
/u/ 1.    470 1. -103 1.    549 1.  -55 1.   496 1.   21
2.    483 2. -108 2.    436 2.   12 2.   622 2. -116
3.    450 3.  -47 3.    642 3.  -94 3.   513 3.   23
X    468 X  -86 X    542 X  -46 X    544 X  -24
lxxxi
Total X    573 X  -86 X    582 X  -54 X    575 X  -35
SD 29 SD 47 SD  69
Table 25: Control Participant #CF01
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    522 1.     81 1.    534 1.     77 1.    668 1.    186
2.    533 2.     96 2.    516 2.     93 2.    586 2.    122
3.    549 3.     98 3.    863 3.    101 3.    613 3.    149
X    535 X     92 X    638 X     90 X    622 X    152
/a/ 1.    720 1.     61 1.    476 1.     82 1.    444 1.    107
2.    678 2.    122 2.    553 2.     85 2.    613 2.    133
3.    560 3.     70 3.    505 3.    103 3.    551 3.     96
X    653 X     84 X    511 X     90 X    536 X    112
/u/ 1.    579 1.     89 1.    596 1.    101 1.    808 1.    149
2.    594 2.     71 2.    550 2.     55 2.    994 2.    133
3.    543 3.     85 3.    480 3.     80 3.    653 3.    147
X    572 X     82 X    542 X     79 X    818 X    143
Total X    587 X     86 X    564 X     86 X    659 X    136
SD   18 SD   15 SD   26
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    473 1.     12 1.    482 1.     16 1.    659 1.   -134
2.    545 2.     13 2.    608 2.   -117 2.   1078 2.   -165
3.    517 3.     20 3.    638 3.   -179 3.    542 3.   -106
X    512 X     15 X    576 X    -93 X    760 X   -135
/a/ 1.    815 1.   -106 1.   1017 1.   -124 1.    794 1.   -200
2.    559 2.   -119 2.    562 2.    -84 2.    666 2.   -121
3.    620 3.   -112 3.    781 3.   -140 3.    667 3.    -90
X    665 X   -112 X    787 X   -116 X    709 X   -137
/u/ 1.    832 1.   -115 1.    674 1.   -133 1.    549 1.   -120
lxxxii
2.    678 2.   -144 2.    344 2.    -49 2.    765 2.     44
3.    568 3.    -90 3.    601 3.   -142 3.    566 3.   -113
X    693 X   -116 X    540 X   -108 X    627 X    -63
Total X    623 X    -71 X    634 X   -106 X    699 X   -112
SD   66 SD    59 SD    67
Table 26: Control Participant #CF02
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    597 1.     78 1.    546 1.     63 1.    650 1.     97
2.    551 2.     50 2.    671 2.     79 2.    546 2.     89
3.    624 3.     47 3.    824 3.     85 3.    629 3.    111
X    591 X     58 X    680 X     76 X    608 X     99
/a/ 1.    596 1.     74 1.    569 1.     89 1.    638 1.    117
2.    820 2.     56 2.    601 2.     84 2.    577 2.     92
3.    270 3.     45 3.    574 3.     80 3.    638 3.     95
X    562 X     58 X    581 X     84 X    618 X    101
/u/ 1.    586 1.    100 1.    535 1.     80 1.    679 1.     98
2.    530 2.     65 2.    533 2.     69 2.    572 2.     89
3.    582 3.    109 3.    518 3.     73 3.    575 3.     81
X    566 X     91 X    529 X     74 X    609 X     89
Total X    573 X     69 X    597 X     78 X    612 X     96
SD   23 SD    8 SD   11
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    723 1.   -142 1.    586 1.    -79 1.    767 1.   -106
2.    617 2.   -116 2.    619 2.   -109 2.    713 2.    -68
3.    763 3.  -152 3.    628 3.    -96 3.    658 3.    -83
X    701 X   -137 X    611 X    -95 X    713 X    -86
/a/ 1.    639 1.   -124 1.    691 1.    -85 1.    701 1.   -134
2.    629 2.   -113 2.    754 2.   -129 2.    634 2.    -98
3.    639 3.   -127 3.    679 3.    -79 3.    675 3.    -65
lxxxiii
X    636 X   -121 X    708 X    -98 X    670 X    -99
/u/ 1.    578 1.   -108 1.    679 1.    -97 1.    681 1.   -100
2.    612 2.   -118 2.    585 2.     32 2.    654 2.    -87
3.    638 3.   -136 3.    677 3.   -100 3.    681 3.   -108
X    609 X   -121 X    647 X    -55 X    672 X    -98
Total X    649 X   -126 X    655 X    -83 X    685 X    -94
SD    15 SD    46 SD    21
Table 27: Control Participant #CF03
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    438 1.     33 1.    438 1.     60 1.    472 1.     74
2.    368 2.     41 2.    526 2.     87 2.    447 2.     56
3.    483 3.     62 3.    446 3.     52 3.    486 3.     81
X    430 X     45 X    470 X     66 X    468 X     70
/a/ 1.    610 1.     84 1.    472 1.     45 1.    483 1.    104
2.    658 2.     66 2.    565 2.     47 2.    507 2.     41
3.    631 3.     73 3.    490 3.     43 3.    438 3.     64
X    633 X     74 X    509 X     45 X    476 X     70
/u/ 1.    378 1.     55 1.    455 1.     53 1.    652 1.     56
2.    447 2.     45 2.    473 2.     55 2.    400 2.     63
3.    547 3.     33 3.    433 3.     56 3.    412 3.     53
X    457 X     44 X    454 X     55 X    488 X     57
Total X    507 X     54 X    478 X     55 X    477 X     66
SD   18 SD   13 SD   19
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    483 1.     24 1.    368 1.     26 1.    509 1.     32
2.    605 2.   -101 2.    405 2.     29 2.    533 2.     32
3.    618 3.   -153 3.    508 3.     18 3.    419 3.     28
X    569 X    -77 X    428 X     24 X    487 X     31
lxxxiv
/a/ 1.    489 1.    -97 1.    567 1.     19 1.    516 1.     25
2.    474 2.     20 2.    498 2.     25 2.    537 2.     26
3.    490 3.     10 3.    470 3.     21 3.    477 3.     43
X    484 X    -22 X    512 X     22 X    510 X     31
/u/ 1.    410 1.     23 1.    455 1.     41 1.    539 1.   -137
2.    473 2.     19 2.    495 2.     32 2.    575 2.   -154
3.    445 3.     24 3.    425 3.     16 3.    388 3.     25
X    443 X     22 X    458 X     30 X    501 X    -89
Total X    499 X    -26 X    466 X     25 X    499 X     -9
SD   70 SD    8 SD    78
Table 28: Control Participant #CF04
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    631 1.  101 1.    585 1.   87 1.    584 1.   84
2.    478 2.   71 2.    486 2.   88 2.    562 2.  134
3.    513 3.  104 3.    671 3.   69 3.    572 3.   91
X    541 X   92 X    581 X   81 X    573 X  103
/a/ 1.    457 1.   73 1.    411 1.   49 1.    549 1.  123
2.    587 2.   99 2.    478 2.   96 2.    477 2.  118
3.    527 3.   80 3.    479 3.   88 3.    577 3.   82
X    524 X   84 X    456 X   77 X    534 X  108
/u/ 1.    784 1.  134 1.    694 1.   77 1.    598 1.   33
2.    497 2.   52 2.    605 2.   91 2.    547 2.  100
3.    490 3.   86 3.    595 3.   70 3.    602 3.   85
X    590 X   87 X    631 X   79 X    582 X   73
Total X    552 X   88 X    556 X   79 X    563 X   95
SD  26 SD 15 SD 30
/b/ /d/ /g/
Duration VOT Duration VOT Duration VOT
/i/ 1.    471 1.   29 1.    650 1.   31 1.    485 1.   23
2.    482 2.   34 2.    607 2.   32 2.    795 2.   31
lxxxv
3.    475 3.   32 3.    566 3.   24 3.    504 3.   27
X    476 X   32 X    608 X   29 X    595 X   27
/a/ 1.    581 1.  -62 1.    564 1.   24 1.    436 1.   19
2.    794 2.   37 2.    427 2.   19 2.    530 2.   23
3.    514 3.   31 3.    526 3.   26 3.    594 3.   24
X    630 X    2 X    506 X   23 X    520 X   22
/u/ 1.    840 1.   22 1.    784 1. -244 1.    546 1.   25
2.    572 2.   15 2.    818 2.   35 2.    524 2.   17
3.    516 3.   12 3.    591 3.   22 3.    527 3.   33
X    643 X   16 X    733 X  -62 X    532 X   25
Total X    583 X   17 X    616 X   -3 X    549 X   25
SD 31 SD 90 SD  5
Table 29: Control Participant #CF05
/p/ /t/ /k/
Duration VOT Duration VOT Duration VOT
/i/ 1.    496 1.   57 1.    508 1.   70 1.    511 1.   81
2.    589 2.   90 2.    476 2.  100 2.    579 2.   98
3.    425 3.   71 3.    708 3.   52 3.    493 3.   77
X    503 X   73 X    564 X   74 X    528 X   85
/a/ 1.    617 1.   90 1.    408 1.   62 1.    555 1.   88
2.    816 2.   91 2.    470 2.   69 2.    667 2.   81
3.    425 3.   43 3.    618 3.   57 3.    474 3.   70
X    619 X   75 X    499 X   63 X    565 X   80
/u/ 1.    910 1.  137 1.    456 1.   72 1.    631 1.   42
2.    627 2.   62 2.    596 2.   80 2.    427 2.   68
3.    546 3.   57 3.    389 3.   51 3.    452 3.   79
X    694 X   85 X    480 X   68 X    503 X   63
Total X    605 X   78 X    514 X   68 X    532 X   76
SD 28 SD 15 SD 16
/b/ /d/ /g/
lxxxvi
Duration VOT Duration VOT Duration VOT
/i/ 1.    856 1.  -79 1.    805 1.   24 1.    566 1.   36
2.    680 2.  -52 2.    632 2.  -88 2.    926 2. -150
3.    570 3. -114 3.    480 3.  -35 3.    648 3.  -59
X    702 X  -82 X    639 X  -33 X    713 X  -58
/a/ 1.    583 1.   33 1.    598 1.   23 1.    693 1. -173
2.    530 2.   15 2.    490 2.   12 2.    705 2. -138
3.    531 3. -117 3.    438 3.   17 3.    600 3.  -48
X    548 X  -23 X    509 X   17 X    666 X -120
/u/ 1.    807 1. -123 1.    588 1.  -79 1.    438 1.   25
2.    750 2.  -87 2.   1106 2. -109 2.    712 2.  -76
3.    521 3.  -92 3.    705 3. -179 3.    511 3.   39
X    693 X -101 X    800 X -122 X    554 X    -4
Total X    647 X  -69 X    649 X  -46 X    644 X   -61
SD 57 SD 72 SD  82
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